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ABSTRACT
Mononuclear phagocytes play a critical role in defending the host against 
foreign organisms and in regulating the behavior of other cells. A characteristic 
feature of macrophages is their ability to infiltrate tumors. Human malignant cells 
secrete low molecular size proteins that attract peripheral blood monocytes and 
may be responsible for the accumulation of tumor associated macrophages 
observed in vivo. One such chemoattractant, monocyte chemoattractant protein-1 
is produced by smooth muscle cells and a human glioma cell line.
Monocyte chemotactic factors produced by different malignant cell types 
were isolated by immunoprecipitation and then monocyte chemotactic activity was 
assayed. The results demonstrated that nine of thirteen human malignant cell lines 
synthesized detectable levels of MCP-1. In each case the chemotactic activity was 
completely inhibited by MCP-1 antisera. The four cell lines in which there were no 
detectable levels of MCP-1 in immunoprecipitation experiments also did not 
produce chemotactic activity. The results demonstrated the correlation between the 
production of monocyte chemotactic activity and the synthesis of MCP-1. Therefore, 
the predominant monocyte chemoattractant produced by tumor cells of differing 
origin are related to MCP-1.
Pulse chase experiments using U-105MG human glioma, MG-63
osteosarcoma and vascular smooth muscle cells established that secreted MCP-1
proteins are derived from a smaller, Mr = 9,000 precursor. Secretion of MCP-1
proteins occurs rapidly following processing events in the endoplasmic reticulum- 
Golgi compartment. Post-translational modifications include the addition of O-linked 
carbohydrates and sialic acid residues. Lectin blot analysis showed that 
disaccharide galactose-B1-3D-N-acetyl galactosamine and sialic acid or N-acetyl- 
glucosamine are present on the 13 kD MCP-1 isoform but not the 9 kD MCP-1 
isoform. Glycosylation of the 13 kD isoform does not appear to significantly change
either its antigenic properties or its capacity to induce monocyte migration.
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INTRODUCTION AND STATEMENT OF PROBLEM
Monocytes and macrophages play an essential role in host defence, and 
are involved in situations such as inflammation and tumor formation. Chemotaxis 
is the mechanism by which monocytes are directed to a site. Human malignant 
cells secrete low molecular size proteins that attract peripheral blood monocytes 
and may be responsible for the accumulation of tumor associated macrophages 
observed in vivo. Many cell types including U-105 MG human glioma cells and 
vascular smooth muscle cells have been shown to express factors that stimulate 
chemotaxis. The chemotactic activity produced by the latter two cell types has 
been termed SMCCF (smooth muscle cell chemotactic factor) and MCP-1 
(monocyte chemoattractant protein-1) respectively. These chemotactic proteins 
produced by different cell types appear to have different molecular masses. The 
questions raised here are: (1) Is the constitutive production of chemotactic factors 
a property of all or most malignant cells, or is it determined by tissue origin of the 
malignant cells? (2) How important is this chemotactic factor for macrophage 
recruitment in tumors; i.e., is an MCP-1 related chemotactic factor responsible for 
all the monocyte chemotactic activity produced by these malignant cells. (3) Are 
chemotactic factors produced by malignant and normal cells related? (4) If they
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are related, what accounts for their microheterogeniety. (5) Does this chemotactic
factor stimulate activities in monocytes other than chemotaxis? The goals of my 
thesis project are stated as follows:
1. To identify monocyte chemotactic activity produced by malignant 
cells of different origin and to investigate potential relationships 
between the monocyte chemotactic factors produced by tumor cells 
and smooth muscle cells.
2. To investigate the apparent microheterogeneity of MCP-1 produced 
in tumor cells and smooth muscle cells.
3. To elucidate the processing pathway and post-translational 
modification of MCP-1.
4. To purify the two predominant isoforms of MCP-1 to establish the 
basis for further functional studies.
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LITERATURE REVIEW
MONOCYTES AND MACROPHAGES
Mononuclear Phagocytes
Mononuclear phagocytes refer to a class of leukocytes that consists of 
monocytes and macrophages. Monocytes are large mononuclear leukocytes (16- 
22 urn in diameter) that normally constitute 3-7% of the leukocytes of the 
circulating blood. The nucleus is usually indented or slightly folded (Wintrobe and 
others, 1981). Macrophages are derived from circulating monocytes and are fixed 
within tissues especially in lymph nodes, spleen, bone marrow, and loose 
connective tissue. These cells are widely distributed in the body and vary in 
morphology and motility. Most macrophages are large, long-lived cells with a 
nearly round nucleus and have abundant endocytic vacuoles, lysosomes, and 
phagolysosomes (Wintrobe and others, 1981). Peripheral blood monocytes are 
recruited to the tissue where inflammation or injury occurs. These cells then 
transform into macrophages that are functionally and morphologically different from
3
the cells described above.
Monocyte/Macrophage Derivation
The monocyte originates in bone marrow as pluripotent stem cells, which 
can differentiate toward either granulocytic, monocytic, erythroid, or 
megakaryocytic cell lineages (reviewed in (Cannistra and others, 1988), (Johnston, 
1988)). These self renewing cells develop into the clonogenic cells which form 
colonies of undifferentiated blasts. The individual cells of a blast cell colony may 
form a secondary colony for granulocytes and monocytes, known as the colony­
forming unit of granulocyte-monocyte (CFU-GM). Glycoprotein hormones termed 
colony-stimulation factors induce differentiation of a cell into a monoblast, which 
further differentiates into a promonocyte, the first morphologically identifiable cell 
in the series. The transit time in the bone marrow from the first monocytic 
precursor to mature monocyte is believed to be about six days. Newly formed 
monocytes may remain in the marrow for one day. Human monocyte circulation 
in the bloodstream has been found to have a half-life of approximately three days. 
Monocytes in the circulation are heterogeneous regarding cell density, size, 
morphology, and surface antigens. Under normal condition (without localized 
inflammation), monocyte migration into the different tissues is a random 
phenomenon. These monocyte-derived macrophages are called resident 
Once in the tissues, mononuclear phagocytes probably do not
4
macrophages.
reenter the circulation. They undergo transformation into tissue macrophages with
morphological and sometimes functional properties that are characteristic for the 
tissue in which they reside. Specialized tissue macrophages have specific names 
at given sites, e.g., Kupffer cells within the liver, alveolar macrophages in the lungs, 
and peritoneal macrophages in the peritoneal cavity. Such transformation is 
presumably a response to tissue-specific stimuli. The life span of individual 
macrophages in human tissues is believed to be months, but precise data are not 
available. The terminal stage of development in the mononuclear-phagocyte line 
is the multinucleated giant cell.
Monocyte/Macrophage Activation
The most important step in the maturation of mononuclear phagocytes is 
the lymphokine-driven conversion of the normal resting cell to the "activated 
macrophage". Macrophages that have not been specifically stimulated are 
generally called resident macrophages (West, 1990). Activation of mononuclear 
phagocytes refers to the changes in biochemical and functional parameters 
observed after treatment with various stimuli (West, 1990). The stimulated state 
that is associated with significant tumor cytolysis or destruction of intracellular 
parasites has been accepted as a definition of the fully activated macrophage
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(West, 1990). As mononuclear phagocytes are activated, other biochemical
properties of these cells are altered. There is decreased expression of cell surface 
transferrin receptors, increased expression of cell surface la antigen, enhanced 
respiratory burst activity, decreased chemotaxis, and release of lysosomal 
enzymes. With further stimulation activated mononuclear phagocytes synthesize 
and secrete various biochemical messenger molecules including prostaglandins, 
leukotrienes, and protein cytokines. They also change morphologically (Johnston, 
1988), becoming bigger and displaying pronounced ruffling of the plasma 
membrane. Activated mononuclear phagocytes also display an increased capacity 
for adherence and spreading on surfaces, formation of pseudopods, and 
increased numbers of pinocytic vesicles.
Monocyte/Macrophage Functions
Mononuclear phagocytes carry out the fundamental protective functions of 
ingesting and killing invading organisms. They play an essential part in the 
development of specific immune response by presenting antigen to lymphocytes 
and serve as supportive, "accessory" cells to lymphocytes. Mononuclear 
phagocytes also facilitate normal wound healing by producing cytokines, which 
could affect epithelium and fibroblast migration, proliferation and extracellular matrix
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production (Nathan, 1987). Immunoregulatory factors produced by mononuclear
phagocytes are very important in host defense and inflammation.
The macrophage is an extraordinarily active secretory cell (Nathan, 1987). 
Approximately 100 distinct substances have been identified as secreted by 
macrophage. Briefly, secretory products of mononuclear phagocytes include 
cytokines, growth factors, complement components, coagulation factors, enzymes, 
and proteins of the extracellular matrix. In addition, mononuclear phagocytes 
produce binding proteins for metals, lipids and biotin, sterol hormones, and 
reactive oxygen and nitrogen intermediates. Evaluation of the importance of 
macrophages requires consideration of the complexity of their secretory products. 
These include individual products with multiple activities, multiple products with 
similar activities, multiple cell sources and product interactions.
Phagocytosis - An important function of mononuclear phagocytes includes 
the ingestion and killing of pathogens. The phagocytosis of invading organisms 
can be affected by the presence or absence of opsonins (antibody, complement, 
and perhaps, fibronectin) for the invader and by the inherent surface properties 
of the microorganism (Johnston, 1988). It is believed that mononuclear 
phagocytes have to adhere first to and then phagocytose invading organisms.
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Therefore, adhesion molecules on macrophage surfaces may be essential to
phagocytosis. Enhanced microbicidal capacity is relevant to increased activity in 
the phagocytosis-associated respiratory burst, i.e., the conversion of oxygen to 
toxic metabolites, including superoxide anion and hydrogen peroxide. Another 
important phagocytic function of macrophages is their ability to dispose of cells 
that are damaged or dying, such as removing tissue debris in normal wound 
healing.
Lymphocyte activation - Macrophages function as antigen presenting cells. 
They process the antigen intracellularly first, then present it to T helper cells with 
la molecules, a Major Histocompatibility Complex (MHC) class II antigen on the 
macrophage surface (Johnston, 1988). The presentation of antigen stimulates T- 
lymphocyte proliferation and lymphokine production. Mononuclear phagocytes 
directly or indirectly participate in B-lymphocyte proliferation and antibody 
production by releasing cytokines. For example, IL-1 produced by macrophages 
could induce T lymphocytes to produce IL-2 that is a growth factor for lymphocyte 
(rev. in Dinarello, 1991).
Tumor killing - The activity of mononuclear phagocytes against tumors may
8
not involve the phagocytic process. Macrophage-mediated tumoricidal cytotoxicity
can be accomplished by direct contact between effector and target cells. 
Macrophages may kill tumor cells by means of secreted products, including 
lysosomal enzymes, oxygen metabolites such as hydrogen peroxide, cytolytic 
proteinases, and tumor necrosis factor-alpha. Mononuclear phagocytes also are 
the major producers of interleukin-1 (IL-1) and interleukin-6 (IL-6), both of which 
may be involved in tumoricidal action (Dawson, 1991). Tumoricidal activity could 
be due to either a direct effect of the cytokine or an indirect effect by stimulation 
of effector T cells with anti-tumor potential. Proteolytic enzymes on the surface 
membrane of mononuclear phagocytes could play a role in tumor rejection 
(Johnston, 1988).
Essential to the monocyte's protective function is its capacity to undergo 
diapedesis across the endothelial wall of blood vessels and migration to inflamed 
sites. Chemotactic factors for monocytes include complement products and 
chemoattractants derived from neutrophils, lymphocytes, tumor, other tissue cells 
and microorganism. Monocytes migrate to infected sites or tumors in response
9
to chemotactic factors.
CHEMOTAXIS
Chemotaxis is the directional locomotion of organisms toward sources of 
chemical attractants, i.e., chemotactic factor (rev. in Wilkinson and others, 1988). 
In contrast, Chemokinesis is an increased random locomotion. Chemotaxis is one 
of the major mechanisms by which cells which defend the body against infection 
are directed to sites of microbial invasion and tissue injury. Chemotactic factors 
are ligands that induce a chemotactic response, i.e., directional locomotion in a 
gradient. The chemotactic factors of major interest are formyl peptides, C5a 
component of complement and leukotrine B4 (LTB4). These factors are 
chemotactic to both neutrophils and mononuclear phagocytes. In recent years, 
neutrophil-specific and monocyte-specific chemoattractants have been identified.
Mechanism of Chemotaxis
Wilkinson and co-workers demonstrated that leukocytes are spherical and 
immotile in the absence of an attractant and an adherent surface (Wilkinson and 
others, 1988). Soon after addition of chemotactic factors, cells begin to change 
shape within 30 sec. The cells polarize into an anterior lamellipodium and 
posterior tail in 2-3 min. Meanwhile, contraction waves appear on the cell surface, 
which move down the cell from front to back. If the cell is allowed to adhere to,
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or to gain traction from a surface, these contraction waves become locomotion.
Wilkinson has described how the cells respond to chemotactic factors in 
detail (Wilkinson and others, 1988). He postulated that polarization is 
accompanied by receptor redistribution. The receptors move to one end of the 
cell where the initial signal of external stimuli is received, which becomes the front 
of the polarized cell. A model for monocyte recruitment during an inflammatory 
episode is as follows. Tumor cells or inflamed tissue cells produce 
chemoattractants for monocytes. The chemoattractants spread out from the 
source (inflamed area) and form a gradient from the lesion. Monocytes receive 
the signal from a specific direction, polarize and move along the gradient of 
chemoattractants. Most of the receptors are now at the front of the cell, which 
ensures that the cell will continue to move forward to the chemoattractant source. 
When the cells move into the inflamed area, they are surrounded by evenly 
distributed chemoattractants. The receptors become occupied simultaneously at 
many points on the monocyte surface and the cell is unable to show a clear 
anteroposterior polarization. At this point, monocytes end their directed migration 
and stay at the inflamed site to perform their functions. The entire process of 
directed migration depends on the gradient and optimal concentration of a
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chemotactic factor.
Cell Moving Force
Two hypotheses regarding the cell moving force have been described by 
Stossel (Stossel, 1990). The first hypothesis originates from a phenomenon in 
pseudopods, solid-to-liquid transitions. The cells are driven forward by a 
propulsive force of this solid to liquid transition. With the discovery of muscle 
proteins in motile nonmuscle cells, a second sliding-filament model was suggested. 
However, new evidence seems to favor the first theory of sol-to-gel 
transformations. Major effector molecules and mechanisms of control are 
described as follows. External molecular signals, such as chemoattractants, bind 
to their receptors on the mobile cell surface, which activates many molecules of 
the cell, including integrins. Integrins are a family of proteins, which regulates cell 
adhesion and migration. Through the cytoplasmic domain of the integrin, an 
external signal causes changes of cytoskeletal components such as actin, which 
is a key factor in pseudopod formation. The actin-disassembly phase starts at 
when an external signalling molecule binds to a cell surface receptor. The function 
of many cell adhesion or migration molecules are calcium dependent. 
Chemoattractants also induce calcium release from internal storage vesicles into 
the peripheral cytoplasm. There, calcium activates several molecules, including 
gelsolin. Activated gelsolin breaks down the actin network in the resting cell,
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resulting in an increased number of particles in the cortical cytoplasm. The latter
increases osmotic pressure and induces a fluid flow into the region of actin 
breakdown. The fluid distorts the membrane into the shape of a pseudopod. 
Meanwhile, free actin molecules are attached by an inhibitory molecule, profilin, 
and the elongating end of existing filments are attached by gelsolin. These 
processes prevent new actin filment formation or elongation. After these events 
reach a maximum, the reverse process begins. The end of the actin filaments with 
gelsolin molecules diffuses to the plasma membrane, where it binds to a class of 
lipids, known as polyphosphoinositides, frequently with phosphatidylinositol. These 
phospholipids somehow break the gelsolin-actin complex apart and dissociate 
actin profilin complexes. Once actin is released from the inhibitory action of 
profilin, molecules can aggregate to form filments. In addition, once gelsolin is 
dissociated from the elongating ends of existing filaments, the filaments are again 
free to grow through the addition of newly released actin molecules. Therefore, 
the pseudopod is stabilized by the actin network. When the pseudopod is formed 
by an actin network, the next cycle of disassembly can begin with the present 
pseudopod as the new starting point. By repeating the cycle of gelation and 
solubilization, the cell continually generates osmotic forces that move the cell
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forward.
MACROPHAGE INFILTRATION
Leukocytes are the major cellular defense mechanism against foreign 
organisms following infection or tissue injury. Their locomotion serves to allow 
them to leave the blood and to accumulate at a site of infection or tissue injury.
Inflammation and Leuokocyte Accumulation
During normal blood flow blood cells, including leukocytes, travell in the 
center of the vessel. Leukocytes move to the periphery of the cross-sectional 
lumen and adhere to the endothelial cells of the vessels, process known as 
margination at sites of slow blood flow. Under physiological conditions, 
margination is transient, and the stationary cells rejoin the circulating pool. 
However, in postcapillary venules near inflamed sites, margination is increased. 
Marginated cells leave the vessel by crawling through gaps between endothelial 
cells and across the vascular basement membrane into the tissue (Wilkinson and 
others, 1988) (vanFurth and Sluiter, 1986).
The movement of leukocytes through tissue is thought to involve the 
expression and "activation" of specific cell surface proteins that mediate cell 
attachment. These molecules include integrins, selectins and the immunoglobulin 
superfamily of adhesion molecules (rev. in Sringer, 1990). Integrins are a family
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of cell surface proteins that mediate cell adhesion. Selectins are a group of
molecules with a N-terminal lectin domain and contribute to cell adhesion. The 
immunoglobulin superfamily consists of adhesion receptors, which share the 
immunoglobulin domain and include the antigen-specific receptors of T and B 
lymphocytes. Adhesion is very important to a cell. It provides anchorage, cues 
for migration, and signals for growth and differentiation (Springer, 1990).
Inflammatory mediators also stimulate adhesion molecule expression on 
endothelium, including endothelial-leukocyte adhesion molecule-1 (ELAM-1) and 
intercellular cell adhesion molecule (ICAM). The infiltration of leukocytes shows a 
high degree of specificity in vivo (Butcher, 1990). This selectivity can be controlled 
at several levels. One level of control is the adhesion of a given type of leukocyte 
to vascular endothelium. Adhesion glycoproteins specific for lymphocytes, called 
"addressins", have been identified on endothelial cell surfaces (Butcher, 1990). 
Likewise, ELAM-1 and ICAM-1 or ICAM-2 supports adhesion of neutrophils and, 
to a lesser extent, peripheral blood monocytes to vascular endothelium (Bevilacqua 
and others, 1989), (Springer, 1990). VCAM (vascular cell adhesion molecule), 
found on vascular endothelium, is specific for monocyte adhesion to endothelium 
(Cybulsky and others, 1991).
Other factors which may influence cell accumulation are cell adhesion
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molecules on leukocytes. Mononuclear phagocytes adhere to substrata and gain
traction for locomotion from these adhesive contacts. The beta-2 family (LFA-1, 
Mac-1, pi 50,95 molecules) and alpha-4 integrins are important for these contacts 
(rev. in Arnaout, 1990, Hemler and others, 1990). Other adhesive mechanisms 
probably contribute. There is presumably an optimum interaction with the 
substratum. At the optimum interaction, forces of attachment and detachment are 
balanced to allow an optimal locomotion, and above or below this optimum, 
locomotion is less efficient. Chemotactic factors produce transient changes in cell- 
to-cell adhesion over periods of a few minutes and may produce complex changes 
up to 1 hr. The chemoattractant fMLP induces adhesion molecule expression of 
beta-2 family on neutrophils and monocytes (Miller and others, 1987), which may 
increase leukocyte adhesion and migration. The responses of both endothelium 
and leukocytes to invading organisms and inflammatory mediators could contribute 
to leukocyte accumulation of infectious or injured tissue.
A proposed model for cell accumulation in tumors or other forms of 
inflammation probably includes the following steps: First, invading organisms or 
injured tissue cells produce inflammatory mediators. These mediators may 
increase leukocyte margination and activate or induce the expression of adhesion 
molecules on both vascular endothelium and lekocytes. Second, marginating
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lekocytes bind chemotactic factors that are locally generated, and polarize toward
the direction of the signal. Third, polarized cells adhere to endothelium by 
adhesion molecules and gain traction from these adhesive contacts for locomotion. 
Fourth, these leukocytes diapedeses across the endothelial wall of blood vessels, 
extravasate into the tissue spaces and finally migrate to the inflamed site along 
positive gradients of chemotactic factors.
Tumors and Macrophages
Tumors are characterized by a macrophage infiltration, which frequently 
constitute 20-30% of a tumor's cellular mass (Carr, 1977). The infiltration of tumors 
by tumor-associated macrophages has the potential to dramatically affect tumor 
growth. This includes the capacity to stimulate tumor growth or induce tumor 
regression. The capacity of macrophages to enhance or inhibit the growth of 
neoplastic cells is mediated by the elaboration of soluble regulatory factors 
(Beutler and others, 1986), (Johnston, 1988), (Nathan, 1987). Macrophages can 
inhibit tumor cell proliferation and exert tumoricidal effects. Inhibition of tumor 
growth may be mediated through production of factors such as tumor necrosis 
factor (TNF), transforming growth factor-beta (TGF-beta), or interferon-alpha 
(IFN-alpha). TNF causes apoptosis of the tumor cells (Larrick and Wright, 1990).
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Both TGF-beta and IFN-alpha have the capacity to inhibit proliferation of tumor
cells (Ramsdell, 1991) (Krown, 1991). Mononuclear phagocytes are also a major 
source of IL-1 and IL-6 both of which may be involved in tumoricidal action 
(Dawson, 1991). Although tumor associated macrophages have the potential to 
inhibit tumor growth (Assoian and others, 1987) (Fleit and others, 1981) (Carswell 
and others, 1975), tumors grow in the presence of tumor associated 
macrophages. Factors produced by activated macrophages can stimulate the 
growth of a variety of cell types including epithelial, endothelial, immune and 
connective tissue cells (Shimokado and others, 1985) (Martinet and others, 1986) 
(Baird and others, 1985) (Dinarello, 1984) (Wewers, 1984) (Rappolee and others, 
1988) (Madtes and others, 1988). Some macrophage-produced growth-inducing 
factors include platelet-derived growth factor, fibroblast growth factor, and 
transforming growth factor-alpha. Macrophages may also affect the behavior of 
tumors through the production of angiogenesis factors that increase vascular 
support for tumor growth (Polverini and others, 1977). It was formerly thought 
that mononuclear phagocytes associate with a tumor by immune recognition 
(Moore and others, 1977), however, there is little correlation between 
immunogenicity and the level of tumor associated macrophages. Lack of tumor 
associated macrophages in animals with destroyed bone marrow system (rev. in
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mantovani and others, 1986) suggests that tumor associated macrophages were
recruited from circulating blood. Bottazzi and co-workers reported that tumor 
infiltration by macrophages in animals is correlated with the production of 
monocyte chemoattractants by the tumor cells in vivo (Bottazzi and others, 1983). 
It is now generally accepted that tumor associated macrophages are derived from 
peripheral blood monocytes. Monocytes infiltrate the tumor from the circulation 
(Acero and others, 1984) (McBride, 1986) (Stephens and others, 1978) in 
response to the chemoattractants produced by tumor cells. This finding suggests 
that infiltration of macrophages in tumors is determined by the properties of the 
tumor itself. The ability of a tumor to produce chemoattractants and to regulate 
monocyte recuitment may be important for the tumor prognosis.
Tumor associated macrophages may affect the tumor differently at different 
stages of tumor growth, since cytotoxicity of macrophages may change during 
tumor development (Mantovani and others, 1986). It has been suggested 
(McBride, 1986) that a mutual selection process may take place between tumors 
and tumor-associated macrophages. This mutual selection process may result in 
the modulation of macrophage activity beneficial to tumor growth. The actual 
effect of tumor associated macrophages on tumor growth remains to be
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investigated.
MCP-1 (monocyte chemoattractant protein 1), which also has been called
MCP-1
SMCCF (smooth muscle cell chemotactic factor), is a pro-inflammatory cytokine. 
Unlike C5a or fMLP, MCP-1 is a monocyte specific chemoattractant.
Production of Monocyte Chemoattractant Protein-1 (MCP-1)
It has been reported by Bottazzi and co-workers that tumor cells secrete 
low molecular weight proteins. These proteins attract peripheral blood monocytes 
and may be responsible for the accumulation of tumor-associated macrophages 
observed in vivo (Bottazzi and others, 1983). Tumor produced chemoattractants 
are cationic, monomeric proteins with molecular weight of 12 kD that stimulate 
migration of monocytes but not polymorphonuclear leukocytes or lymphocytes. 
Similar chemotactic proteins are secreted by cultured vascular smooth muscle cells 
(SMC-CF) (Valente and others, 1984), (Valente and others, 1988). Another report, 
by Altman and coworkers (Altman and others, 1975), showed monocyte 
chemotactic activity produced by mitogen-stimulated lymphocytes. Yoshimura and 
his co-workers identified a human monocyte chemotactic protein that they termed 
MCP-1 (Yoshimura and others, 1989). This protein was purified from U-105 MG 
glioma cells and found to exist in two forms: Mr = 13,000 and 15,000. Analysis of
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restriction endonuclease digests of human genomic DNA showed that there is a
single MCP-1 gene and the cDNA sequence predicted a protein with Mr = 8700. 
The authors could not explain the discrepancy between the molecular weights of 
the secreted proteins determined experimentally and the predicted molecular mass 
of MCP-1. MCP-1 comprises a single 76 residue protein chain with blocked 
amino terminus. The cDNA open reading frame codes for a 99 residue protein. 
The first 23 residues correspond to a signal peptide that is typical for the secreted 
protein. The last 76 residues correspond to mature MCP-1.
MCP-1 is assigned to a family of inflammatory cytokines that share 
nucleotide and structural similarities based on the common characteristic feature 
of four half-cystines. These include the JE product, which is secreted by 
fibroblasts in response to growth factor stimulation. The JE cDNA sequence 
shares 68% nucleotide sequence homology with MCP-1. Other putative 
inflammatory proteins share nucleotide sequence homology with MCP-1: an 
inducible lymphocyte gene, pLD78 (36% homology); macrophage inflammatory 
protein, MIP (36% homology); aT cell-specific molecule, RANTES (28% homology); 
and the T cell-specific gene, TCA-3.0 (25% homology) (Furutani and others, 1989).
Many cell types can produce MCP-1 (rev. in Lenard and others, 1990). 
Malignant cells and baboon aortic smooth muscle cells constitutively secrete MCP-
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1 in vitro. However, MCP-1 production in vitro by most normal cell types requires
induction by pro-inflammatory mediators. MCP-1 can be produced by 
lymphocytes, monocytes, fibroblasts and endothelial cells in response to 
inflammatory stimuli such as IL-1, TNF, PHA or LPS.
Biological Functions of MCP-1
Monocyte chemoattractant protein 1 (MCP-1) is a pro-inflammatory cytokine 
that stimulates chemotaxis of peripheral blood monocytes (Valente and others, 
1988) (Yoshimura and others, 1989). Lymphocytes and polymorphonuclear 
leukocytes have no high affinity MCP-1 binding sites and do not migrate in 
response to MCP-1 (Jauchem and others, 1982); (Yoshimura and others, 1990) 
MCP-1 differs from most other chemoattractants because it is specific for 
monocytes.
Besides stimulating chemotaxis, MCP-1 induces calcium flux and respiratory 
burst activity in monocytes (Zachariae and others, 1990); (Rollins and others, 
1991). There is also evidence that MCP-1 can stimulate monocyte-mediated 
inhibition of tumor growth in vitro and in vivo (Matsushima and others, 1989); 
(Rollins and others, 1991). Macrophages also secrete MCP-1 directly, in
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response to bacterial or LPS.
Besides its putative role in host defense, MCP-1 may be an important
mediator in human disease, e.g., tumor growth and atherosclerosis, which are 
characterized by macrophage accumulation. This is supported by evidence that 
MCP-1 is expressed in atherosclerotic lesions but not in normal blood vessels 
(YlaHerttuala and others, 1991); (Nelken and others, 1991). Similarly, MCP-1 is 
expressed in human melanoma but not in normal skin (Graves and others, 
unpublished data).
GLYCOPROTEINS
Glycoproteins occur in cells and extracellular matrix. In cells, glycoproteins 
can exist in both soluble or membrane-bound forms. A large variety of protein 
factors, such as enzymes, immunoglobulins, hormones, lectins and structural 
proteins are glycoproteins. The carbohydrate domain of the glycoprotein 
potentially plays important biological roles. It has the potential to stabilize protein 
conformation, specifies human blood types, and in some cases, controls the half- 
life of glycoproteins. Carbohydrates on cell surfaces or extracellular matrix 
proteins also serve as attachment sites during cell-cell or cell-matrix interactions.
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Structures of Glycoprotein
There are less than 15 monosaccharides found in glycoproteins although
more than 200 exist in nature. Hexoses or their simple derivatives are most 
common. Sialic acids, derived from a nine carbon straight-chain sugar known as 
neuraminic acid, occur in many animal glycoproteins.
Carbohydrate-peptide linkage, a characteristic feature of glycoproteins, may 
be one of two different types. One is a N-glycosidic linkage between the anomeric 
carbon of N-acetylglucosamine and the nitrogen of the amide group of asparagine, 
referred as N-linked carbohydrate. The other carbohydrate-peptide linkage is 
called O-linked, which includes N-acetylgalactosamine, galactose, or xylose on the 
one hand, and the hydroxyl groups of serine, threonine, hydroxylysine, or 
hydroxyproline on the other. Rarely occurring O-glycosidic linkages exist between 
L-fucose and threonine. The linkages between serine and a mannose, or a 
disaccharide (Xyl-Glu) or a trisaccharide (Xyl2-Glu) have also been reported 
(Nishimura and others, 1989) (Hase and others, 1990). A single glycoprotein may 
contain more than one type of carbohydrate-peptide linkage.
One of the common structural features of N-linked carbohydrates is their 
inner core consisting of a branched pentasaccharide, trimannosyl-di-N- 
acetylglucosamine {Man3(Glc-NAc)2}. The peripheral mannose residues are always 
substituted either by additional mannose residues, or by two to four disaccharide
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units of galactosyl-beta-1-4-N-acetylglucosamine (N-acetyllactosamine), to which
sialic acid is often attached. In addition, the characteristic amino acid sequence 
at the glycosylated site is always asparaginyl-X-serine or asparaginyl-X-threonine 
(Asn-X-Ser/Thr). X can be any amino acid. However, the presence of this 
sequence is not sufficient for glycosylation of the asparagine residue.
The common structural feature of O-linked carbohydrates is the presence 
of the disaccharide galactosyl-beta-1-3N-acetylgalactosamine linked to serine or 
threonine in many O-glycosidically linked glycoproteins.
Biosynthesis of Glycoproteins
There is no difference in the biosynthetic pathway of polypeptide chains 
between glycoproteins and non-glycosylated proteins. The primary structure of 
polypeptides is controlled by the genetic code, so that all molecules of a given 
protein encoded by same gene are identical. In contrast, oligo- and 
polysaccharides are not primary gene products. Addition of sugar to proteins is 
catalyzed by glycosyltransferases, which transfer sugars from their nucleotides to 
a suitable acceptor. The glycosyltransferases are classified according to the sugar 
transferred, for example, sialyltransferases or galactosyltransferases. The
sequence of a synthesized carbohydrate moiety is controlled indirectly by the
properties of the glycosyltransferases, which are the primary gene products.
This type of synthesis is less accurate and results in microheterogeneity in the 
carbohydrate moiety of glycoproteins. Occasionally, sugar may be added 
nonenzymically to proteins in vivo (Sharon and others, 1981).
The biosynthetic pathway of a polypeptide chain and its N-glycosylation has 
been illustrated (Sharon and others, 1981). Synthesis of the protein is initiated on 
individual ribosomes and continues on polyribosomes. Attachment of the free 
ribosomes to the membrane of the endoplasmic reticulum is mediated by a signal 
sequence, which is present in the first 30 N-terminal amino acids of a peptide 
chain. While the polysomes are forming, the peptides begin to pass through the 
membrane bilayer into the intravesicular space of the endoplasmic reticulum. As 
the ribosome moves along the messenger RNA, translation occurs, and more of 
the newly synthesized peptides enter the intravesicular space. The lipid 
intermediate, dolichol phosphate linked saccharides (G-oligosaccharide) transport 
the hydrophilic sugars into or through the hydrophobic membrane environment to 
the location where attachment of polypeptide chains occurs. G-oligosaccharides 
from the lipid intermediates are transferred to asparagine residues on the growing 
polypeptides. This process may happen soon after these residues get into the 
inner side of the endoplasmic reticulum. The signal peptide is cleaved by
26
'signalase" during the peptide synthesis. The transferred G-oligosaccharide then
is modified and elongated in the Golgi complex. The completed glycoprotein is 
transported to the plasma membrane within a transport vesicle. The vesicle 
membrane fuses with the plasma membrane and the glycoprotein is secreted from 
the cell.
Biosynthesis of O-linked carbohydrates (rev. in Sham and others, 1981) is 
a simpler process than that of the N-linked carbohydrates. One monosaccharide 
at a time is directly added to the growing polypeptide by a transformation of N- 
acetylgalactosamine from UDP-N-acetylgalactosamine to a hydroxyamino acid in 
the polypeptide backbone. Then either different disaccharides or terminal sialic 
acids attach to the protein-linked N-acetylgalactosamine residues.
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METHODS AND RESULTS
The descriptive part of this thesis is divided into four sections. Section A, 
B and C are published papers. Section D is unpublished experiments. I did most 
of the experiments in this thesis. Others contributed to the work in section A, and 
to a lesser extent in section B.
In section A, immunoprecipitation experiments and chemotaxis assays 
demonstrated the correlation between the production of monocyte chemotactic 
activity and the synthesis of MCP-1 (previously called SMC-CF). MCP-1 seems to 
account for most, if not all of the non-latent monocyte chemotactic activity 
produced by tumor cells. The experiments also demonstrated that the production 
of MCP-1 is not determined by the tissue origin of tumor cells.
Section B established that microheterogeneity of MCP-1 was due to 
differences in post-translational modification. MCP-1 produced by baboon smooth 
muscle cells appears to be glycosylated while both glycosylated and non- 
glycosylated forms of MCP-1 are secreted by tumor cells. Pulse chase 
experiments demonstrated that larger MCP-1 proteins are derived from a Mr = 9000 
precursor. Experiments with monensin established that MCP-1 undergoes post- 
translational modification in the endoplasmic reticulum-Golgi complex.
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Deglycosylation experiments determined that post-translational modification of
MCP-1 involves the addition of O-linked carbohydrates and sialic acid residues.
The experiments in section C showed that disaccharide galactose-beta1-3D- 
N-acetylgalactosamine is present on the 13 kD MCP-1 isoform but not the 9kD 
isoform. Glycosylation of the 13 kD isoform does not appear to significantly 
change its antigenic properties and does not affect its capacity to induce 
monocyte migration.
Unpublished experiments in section D demonstrated that proteose-peptone 
elicited peritoneal exudate macrophages respond to MCP-1. The MCP-1 isolation 
protocol is also described in this section.
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Identification o f Monocyte Chemotactic Activity 
Produced by Malignant Cells
D. T. G raves,* Y. L. Jia n g , M. J. W illia m so n , A. J. V alente
Human malignant cells secrete low molecular size proteins that attract peripheral
macrophages observed in vivo. Similar chemotactic proteins are secreted by cultured
by tumor cells o f  differing origin were demonstrated to be related to smooth muscle 
cell—derived chemotactic factor. Thus, a single class o f  chemotactic proteins is 
produced by different cell types, which suggests a common mechanism for the re­
cruitment o f  monocytes and macrophages. These results are significant in view o f the 
potential o f macrophages to affect tumor growth.
A  c h a r a c t e r i s t i c  f e a t u r e  o f  m a c -  an inhibitor}' effect through the productionrophages is their ability to infiltrate of factors such as interferon, tumor necrosistumors. The cellular mass of a solid factor, and transforming growth factor-p
tumor can consist of up to 80% macro- (3, 4). The macrophage content of tumors is
phages (J). Macrophages mav stimulate tu- sustained primarily through the recruitment
mor growth through the production of pro- of circulating monocytes, which undergo
liferative and angiogenic factors (2) or exert maturation in situ to macrophages (5). For-
blood monocytes and may be responsible for the accumulation o f tumor-associated
vascular smooth muscle cells. The predominant monocyte chemoattractants produced
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erly, it was thought that such recruitment 
resulted from immune recognition of neo­
plastic cells (6). This now appears unlikely, 
however, as there is little correlation be­
tween immunogenicitv and the level of tu­
mor-associated macrophages (7).
A mechanism involved in controlling 
monocyte infiltration mat' be the elabora­
tion of monocyte chemoattractants by tu­
mor cells (8). A protein with a relative 
molecular mass (Afr) = 12,000 produced by 
freshly isolated tumors and tumor cell lines 
stimulates chemotaxis of monocytes but not 
polymorphonuclear leukocytes (9). The per­
centage of tumor-associated macrophages 
found in these tumors in vivo was positively 
correlated to the production of monocyte 
chemotactic activity in vitro. Normal cells 
also produce monocyte chemoattractants. A 
monocyte chemoattractant produced by ba­
boon vascular smooth muscle cells, the 
smooth muscle cell-derived chemotactic fac­
tor (SMC-CF), is a basic, monomeric pro­
tein with Mr = 14,400 (10, 11). High-affin- 
itv receptors for SMC-CF have been identi­
fied on the surface of freshly isolated periph­
eral blood monocytes but not on 
polymorphonuclear leukocytes or lympho­
cytes (12). We now report that monocvte 
chemotactic activity' produced by tumor 
cells is antigenicallv related to SMC-CF and 
is the predominant, nonlatent monocyte 
chemoattractant produced in vitro bv tumor 
cells of different origins.
To investigate the relation between the 
monocvte chemotactic factors produced by' 
baboon vascular smooth muscle and tumor 
cells, we performed immunochemical stud­
ies. The SMC-CF was collected from serum- 
free medium conditioned by baboon 
smooth muscle cells, purified to homogene­
ity' (11), and used to generate polyclonal 
antibodies in rabbits. The antiserum to 
SMC-CF blocked SMC-CF-induced mono­
cyte migration (Table 1). When purified 
SMC-CF was incubated first with antise­
rum, SMC-CF-induced chemotactic activity 
was completely inhibited, whereas incuba­
tion with preimmune serum had essentially 
no inhibitory effect. The inhibition of SMC- 
CF in conditioned medium was dependent 
on the concentration of antiserum (Fig. 
1A). SMC-CF antiserum, however, did not 
inhibit monocvte chemotaxis stimulated bv 
another monocyte chemoattractant, formyl- 
methionvl-leucyl-phenylalanine (13), thus 
indicating that the SMC-CF antiserum spe­
cifically inhibits SMC-CF-induced chemo­
taxis. This antiserum specifically immuno- 
precipitated a single protein with Mr = 
14,500 from metabolically labeled baboon 
vascular smooth muscle cells (Fig. IB). The 
same protein was not immunoprecipitated 
with normal rabbit serum or with SMC-CF 
antiserum in the presence of excess unla­
beled SMC-CF.
In initial experiments with malignant cells 
we found that human osteosarcoma cells 
produced factors that were of low molecular 
size, heat stable, cationic, and were chemo-
Table 1. SMC-CF antiserum inhibits the chemo­
tactic activity of purified SMC-CF. Purified 
SMC-CF (5 ng/ml) was incubated with preim­
mune serum or SMC-CF antiserum (final dilution 
1:600) for 2 hours at 37°C and then assayed for 
monocvte chemotactic activity in Bovden cham­
bers as described (71). Chemotactic activity is 
expressed as the average number of human pe­
ripheral blood monocytes migrating per field in 
ten high power (X100) fields (hpf). Each value 
represents the mean of triplicate samples ± SEM.
Solution
Chemotactic 
activity 
(cells per hpf)
SMC-CF 55.7 ± 0.5
SMC-CF + antibody 13.2 ± 0.3
SMC-CF + preimmune serum 48.2 ± 2.8
Buffer 12.4 ± 1.4
Buffer + antibody 12.9 ± 0.2
Buffer + preimmune serum 17.1 ± 0.3
tactic as well as chemokinetic for monocytes, 
as determined by checkerboard analysis (13). 
Because these characteristics were similar to 
those reported for SMC-CF, comparative 
studies were done. Serum-free medium con­
ditioned by MG-63 human osteosarcoma 
cells stimulated monocvte chemotaxis in a 
concentration-dependent manner, demon­
strating activity at concentrations greater 
than a 1:500 dilution (Fig. 2A). This che­
motactic activity could be blocked bv first 
incubating with the SMC-CF antiserum, 
indicating that it is antigenicallv related to 
SMC-CF. The chemotactic activity in the 
osteosarcoma-conditioned medium was also 
inhibited bv SMC-CF antiserum in a con­
centration-dependent manner, whereas in­
cubation with normal rabbit serum had es­
sentially no inhibitory' effect (Fig. 2B). At 
concentrations greater than a 1:1,000 dilu­
tion, SMC-CF antiserum inhibited nearly all 
of the chemotactic activity produced by 
MG-63 cells; thus an SMC-CF-like factor is 
responsible for most if not all of this chemo­
tactic activity'.
Immunoprecipitation of proteins labeled 
with [35S]methionine and released bv MG- 
63 cells identified two SMC-CF—like pro­
teins with Mr of 9,000 and 14,000 (Fig. 
2C). These proteins were not detected bv 
normal rabbit serum or bv SMC-CF antise­
rum in the presence of excess unlabeled 
SMC-CF, demonstrating specificity of the 
immunoprecipitation with SMC-CF antise­
rum. The size of the larger protein is similar 
to that of SMC-CF secreted bv baboon 
vascular smooth muscle cells. The smaller 
protein is not secreted bv vascular smooth 
muscle cells, but can be immunoprecipitated 
from lysates of vascular smooth muscle cells 
incubated with monensin. This finding sug­
gests that the smaller protein is an interme­
diate product formed before secretion bv 
smooth muscle cells (13).
We examined other tumor cell lines and 
found a correlation between the production 
of monocyte chemotactic activity and immu­
noprecipitation of SMC-CF-related pro­
teins (Fig. 3). Of 13 different human malig­
nant cells tested, 9 synthesized detectable 
levels of SMC-CF-like proteins as deter­
mined bv immunoprecipitation with SMC- 
CF antiserum but not with normal rabbit 
serum. Cells that produced SMC-CF-like 
proteins were derived from a melanoma,
Fig. 1. SMC-CF antiserum inhibits SMC-CF A 
activity and specifically immunoprecipitates d 
SMC-CF. (A) Serum-free medium was condi­
tioned bv confluent baboon vascular smooth mus- C  
cle cells for 3 days as described (16), diluted 1:2 20
with buffer, incubated with normal rabbit serum e fc 
( • )  or SMC-CF antiserum (O) for 2 hours, and H « 
then assayed for stimulation of chemotactic activi- 
tv in human peripheral blood monocytes in Bov- z  ^  
den chambers as described (77). Net chemotactic 
activity is expressed as the average number of 
monocytes that migrated per field in ten high 9
power fields (hpf) minus the negative control.
Each value represents the mean of duplicate sam­
ples, which differed bv less than 14% from the 
mean. (B) Baboon vascular smooth muscle cells B 
were metabolicallv labeled for 7 hours with a 
mixture of [3!S]methionine and [35S]cvsteine (to­
tal 400 fiCt/ml) as described (76). Labeling medi­
um was collected and incubated with (lane 1) 
normal rabbit serum, (lane 2) SMC-CF antise­
rum, or (lane 3) SMC-CF antiserum plus excess 
SMC-CF (2.5 |xg). Reduced immunoprecipitates 
were analyzed by SDS-polvacrvlamide gel elec­
trophoresis (PAGE) and fluorographv on 18% 
acrylamide gels. The only protein specifically im­
munoprecipitated bv SMC-CF antiserum had 
AT = 14,500. Each assay is representative of at 
least two experiments.
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Fig. 2. SMC-CF antiserum blocks chemotactic 
activity’ and immunoprecipitates SMC-CF-like 
proteins produced by human osteosarcoma cells. 
All assays are representative of at least two experi­
ments. (A) Serum-free medium conditioned by 
MG-63 human osteosarcoma cells was collected 
as described {16), diluted 1:5 to 1:50,000 in 
buffer with (O) or without ( • )  SMC-CF antise­
rum (1:200), and tested for stimulation of human 
monocyte migration as described in the legend to 
Fig. 1. Chemotactic activity is expressed as the 
average number of human peripheral blood 
monocytes migrating per field in ten high power 
fields. Each value represents the mean of triplicate 
samples ±  SEM. The chemoattractant fMet-Leu- 
Phe (10 nM) was tested as a positive control (24.3 
±  5.2 cells per high power field), and buffer alone 
was the negative control (5.1 ± 1.6 cells per high 
power field). (B) Serum-free medium condi­
tioned bv MG-63 cells diluted 1:2 with buffer 
was incubated with normal rabbit serum ( • )  or 
SMC-CF antiserum (O) (1:10 to 1:1,000,000) 
and tested for stimulation of monocyte chemotax- 
is as described in the legend to Fig. 1. (C) MG-63 
human osteosarcoma cells were metabolicallv la­
beled for 5 hours with [35S]methionine (300 
pCi/ml). Labeling medium was incubated with 
(lane 1) normal rabbit serum, (lane 2) SMC-CF 
antiserum, or (lane 3) SMC-CF antiserum plus 2 
Hg of purified SMC-CF. Immunoprecipitates 
were analyzed by SDS-PAGE and fluorographv 
on 18% acrylamide gels. The only proteins specif­
ically immunoprecipitated had M r of 9,000 and 
14,000. »
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Fig. 3. Tumor cells o f differing origin produce SMC-CF. Fluman tumor cell lines were purchased from 
American Type Culture Collection. Primary human osteosarcoma cell cultures were established from 
two different tumors. (Top) Cells were metabolically labeled with [35S]methionine as described (16). 
Labeled medium was immunoprecipitated with SMC-CF antiserum (even-numbered lanes) or normal 
rabbit serum (odd-numbered lanes). Immunoprecipitates were analyzed by SDS-PAGE and fluorogra- 
phy on 18% acrylamide gels. Specifically immunoprecipitated proteins had M r ranging from 8,000 to 
15,000. (Bottom) Serum-free medium was conditioned by human tumor cells for 48 hours, diluted 
1:8, and tested for stimulation of monocyte chemotaxis as described (11). Half of the samples were 
incubated with SMC-CF antiserum (1:200) before the assay. Each value represents the mean of 
triplicate samples: 0, no stimulation; + , twofold stimulation; + + , threefold stimulation; + + + , four- 
or fivefold stimulation compared to the negative control in buffer alone. Statistical significance of 
chemotactic inhibition was determined bv Student’s t test: *P  <  0.05; * *P  < 0.01; and NS, not 
significant. (Lanes 1 and 2) WM-115, melanoma; (lanes 3 and 4) 5637, bladder carcinoma; (lanes 5 
and 6) MS751, epidermoid carcinoma; (lanes 7 and 8) U-138MG, glioblastoma; (lanes 9 and 10) FIT- 
1080, fibrosarcoma; (lanes 11 and 12) SK-LMS-1, leiomyosarcoma; (lanes 13 and 14) A172, 
glioblastoma; (lanes 15 and 16) RD, rhabdomyosarcoma; (lanes 17 and 18) OS-1, primary' osteosar­
coma; (lanes 19 and 20) SaOS-2, osteosarcoma; (lanes 21 and 22) OS-2, primary' osteosarcoma; (lanes 
23 and 24) MG-63, osteosarcoma; and (lanes 25 and 26) U-2 OS, osteosarcoma. Each assay is 
representative of at least two experiments.
glioblastoma, fibrosarcoma, rhabdomyosar­
coma, and from osteosarcoma. The latter 
included two primary osteosarcoma cell cul­
tures. Four did not produce SMC-CF-like 
proteins; these were derived from a bladder 
carcinoma, epidermoid carcinoma, leiomyo­
sarcoma, and an osteosarcoma. All of the 
cells that synthesized SMC-CF-related pro­
teins produced chemotactic activity that was 
inhibited by SMC-CF antisera. Significant­
ly, the four cell lines tested that did not 
release detectable levels of SMC-CF-like 
proteins in immunoprecipitation experi­
ments also did not produce large amounts of 
chemotactic activity'. Our results emphasize 
the correlation between the production of 
monocyte chemotactic activity' and the syn­
thesis of SMC-CF-like proteins. These data 
also suggest that tissue origin of trans­
formed cells does not determine whether 
significant amounts of SMC-CF-like pro­
teins are produced.
Our studies indicate that the monocyte 
chemotactic activity secreted by malignant 
cells and normal vascular smooth muscle 
cells is associated with a protein or family of 
proteins that share common structural de­
terminants. The SMC-CF-like proteins ap­
pear to be responsible for most, if not all of 
the nonlatent monocyte chemotactic activity' 
produced by several different malignant 
cells. Furthermore, SMC-CF is related to 
the chemotactic protein, MCP-1. This rela­
tion is based on evidence that their amino 
acid composition is similar (11, 14), that the 
amino termini of both are blocked and are 
not deblocked by pvroglutamy'l aminopepti- 
dase (14, 15), and that partial amino acid 
sequence analysis of SMC-CF peptide frag­
ments indicates that there are peptide do­
mains of both proteins that are identical (14, 
15). This single class of proteins suggests a 
common mechanism for the recruitment of 
monocytes and macrophages and provides 
an explanation for the monocyte infiltration 
frequently observed in solid tumors. Macro­
phages have the demonstrated ability to 
affect tumor growth in vivo (4); therefore, 
factors that modulate their chemotaxis may 
be clinically important.
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Chemotaxis is an important step in m onocyte recruit­
ment in inflam m ation, wound healing, and tumor 
growth. We reported previously that m onocyte che- 
motactic activ ity  secreted by m alignant cells and nor­
mal smooth muscle cells is associated w ith a protein or 
fam ily of proteins that are related to the monocyte- 
specific smooth muscle cell-derived chem otactic factor 
(SMC-CF) (Graves, D. T., J iang, Y. L., W illiamson, M. 
J ., and Valente, A. J. (1989) Science 2 4 5 ,1 4 9 0 -1 4 9 3 ) .  
Sim ilar m onocyte chem otactic proteins (MCP-1) pro­
duced by U-105M G  human gliom a cells have also been 
identified (Yoshimura, T., Robinson, E. A ., Tanaka, 
S., Appella, E., Kuratsu, J ., and Leonard, E. J. (1989) 
J. Exp. Med. 169 , 1 4 4 9 -1 4 5 9 ) . We now report that 
the MCP-1 gene is expressed in M G-63 human osteo­
sarcoma and vascular smooth m uscle cells and that 
SMC-CF antiserum  specifically  im m unoprecipitates 
proteins synthesized by U -105M G  gliom a cells. E xper­
im ents w ere undertaken to elucidate the processing  
pathway of M C P-l/SM C -C F-like proteins in each of 
these cell types. These experim ents dem onstrate that 
larger M CP-l/SM C -C F-like proteins are derived from  
a Mr = 9 0 0 0  precursor. Post-translational m odification  
involves the addition of O-linked carbohydrates and 
sialic acid residues. D ifferences in carbohydrate proc­
essing account for the heterogeneity in M C P-l/SM C - 
CF-like proteins produced by d ifferent cell types. S e­
cretion of these proteins occurs rapidly fo llow ing proc­
essing events in the endoplasm ic reticulum -G olgi com­
partment.
Tumors are characterized by a macrophage infiltration, 
which frequently constitute 20-30% of a tumor’s cellular mass 
(1). The infiltration of tumors by tumor-associated macro­
phages (TAM)1 has the potential to dramatically affect tumor 
growth. This includes the capacity to stimulate tumor growth 
or paradoxically induce tumor regression. The capacity of 
macrophages to enhance or inhibit the growth of neoplastic 
cells is mediated by the elaboration of soluble regulatory 
factors (2-4). Factors produced by activated macrophages can
* This study was supported by National Institutes of Health Grants 
DE-07559, DE-08569, and HL-38390. The costs of publication of this 
article were defrayed in part by the payment of page charges. This 
article must therefore be hereby marked “advertisement” in accord­
ance with 18 U.S.C. Section 1734 solely to indicate this fact.
|| To whom correspondence should be addressed. Tel.: 617-638- 
8547.
1 The abbreviations used are: TAM, tumor-associated macro- 
phage(s); SMC-CF, smooth muscle cell-derived chemotactic factor; 
MCP-1, monocyte chemoattractant protein-1; SDS, sodium dodecyl 
sulfate; PAGE, polyacrylamide gel electrophoresis.
stimulate the growth of a wide variety of cell types including 
epithelial, endothelial, immune, and connective tissue cells 
(5-11). In addition, macrophages may stimulate tumor cell 
proliferation indirectly through the production of angiogene­
sis factors that increase the vascular support for tumor growth 
(12). Despite the potential for TAM to inhibit tumor growth 
(13-15), it is apparent that tumors grow in the presence of 
TAM.
It is now generally accepted that most TAM are derived 
from peripheral blood monocytes that are recruited into the 
tumor mass from the circulation (16-19), suggesting that the 
TAM population is in someway regulated by and is a charac­
teristic of the tumor itself. One mechanism thought to be 
important in controlling monocyte infiltration is the elabo­
ration of monocyte chemoattractants by tumor cells (20, 21). 
Our previous studies indicated that malignant cells secrete 
low molecular monocyte chemoattractants which are bio­
chemically and antigenically similar to the monocyte-specific 
smooth muscle cell-derived chemotactic factor (SMC-CF) (22, 
23). Immunoprecipitation experiments with SMC-CF antisera 
demonstrated that SMC-CF-like proteins secreted by vascular 
smooth muscle cells had Mr = 14,500, whereas those produced 
by MG-63 cells had M r = 9,000 and 14,000. A similar monocyte 
chemoattractant was independently identified and termed 
monocyte chemoattractant protein-1, MCP-1 (24). MCP-1 
produced by the U-105MG cell line is a basic protein with an 
apparent Mr = 15,000 and 13,000 on SDS-PAGE. The cDNA 
sequence for MCP-1 was recently published and predicts a 
mature protein core with M r = 8,700 (25). In order to further 
investigate MCP-l/SMC-CF proteins, the experiments de­
scribed below were undertaken. The results demonstrate that 
MCP-l/SMC-CF is synthesized as a low molecular weight 
protein, which is subsequently modified by the addition of O- 
linked carbohydrates and sialic acid residues. The secretion 
of MCP-l/SMC-CF-like proteins occurs rapidly following 
processing events in the endoplasmic reticulum-Golgi com­
partment of the cells.
MATERIALS AND M ETHODS AND RESU LTS2
Expression of MCP-l/SMC-CF Genes—Amino acid com­
position and partial amino acid sequence analysis indicate 
that MCP-1 and SMC-CF are the same protein (23, 25).3 
Results of Northern blot analysis (Fig. 1) demonstrate the 
expression of MCP-1 gene in MG-63 osteosarcoma and vas-
2 Portions of this paper (including “Materials and Methods,” part 
of “Results,” and Fig. 5) are presented in miniprint at the end of this 
paper. M iniprint is easily read with the aid of a standard magnifying 
glass. Full size photocopies are included in the microfilm edition of 
the Journal tha t is available from Waverly Press.
3 A. Valente, K. W att, and C. Schwartz, unpublished data.
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F ig . 1. N orthern blot analysis o f M G-63 osteosarcom a and 
vascular smooth muscle cells w ith  MCP-1 cDNA probe and 
im m unoprecipitation o f SMC-CF like proteins produced by 
U -105M G  human gliom a cells. Total RNA from MG-63 human 
osteosarcoma (lane 1), vascular smooth muscle (lane 2), and SKLMS 
human leiomyosarcoma cells (lane 3) was hybridized with a 32P- 
labeled MCP-1 cDNA probe. U-105MG human glioma cells (lanes 4 -  
6) were metabolically labeled with [3“S]methionine. Labeling medium 
was incubated with normal rabbit serum (4), SMC-CF antiserum (5), 
or SMC-CF antiserum plus 1 fig of purified SMC-CF (6). Immuno- 
precipitates were analyzed by SDS-PAGE and fluorography. Molec­
ular weight standards are indicated.
cular smooth muscle cells. MCP-1 transcripts of approxi­
mately 700 base pairs were clearly detected in MG-63 cells 
and vascular smooth muscle cells and are the same as those 
reported for U-105MG cells (25). If the autoradiograph was 
overexposed, as in Fig. 1, a faint band corresponding to 700 
base pairs was observed in SKLMS leiomyosarcoma cells, 
which do not produce monocyte chemotactic activity, sug­
gesting that the MCP-1 gene is constitutively transcribed at 
very low levels in these cells. Immunoprecipitation experi­
ments with [35S]methionine-labeled U-105MG cells demon­
strate that SMC-CF antiserum specifically immunoprecipi- 
tates proteins with Mr = 9,000, 13,000, and 15,000 which are 
not precipitated by normal rabbit serum or by antiserum in 
the presence of excess antigen, purified SMC-CF. However, 
during the course of several experiments, the Mr = 15,000 
band was occasionally not detected. The reason for this vari­
ation is not known.
Processing Studies—Pulse-chase experiments indicate that 
SMC-CF/MCP-l-like proteins are synthesized as a precursor 
with Mr = 9,000 and subsequently modified to higher molec­
ular weight forms in both U-105MG and vascular smooth 
muscle cells. The prominent intracellular protein specifically 
immunoprecipitated by SMC-CF antiserum at the earliest 
time point in pulse chase experiments had a Mr — 9,000 (Fig. 
2). In U-105MG cells the Mt = 9,000 protein diminished 
intracellularly after a 15-min chase period. Concomitant with 
the reduced intensity of this band was the appearance of a 
higher molecular weight protein with M r = 13,000. On over­
exposure of the fluorograph a faint band, Mr = 15,000, was 
also observed at this time point. After a chase period of 60 
min, MCP-1 intracellular proteins disappeared, suggesting 
that they are rapidly secreted or degraded. The former is 
supported by the appearance of proteins with Mr = 9,000, Mr 
= 13,000, and a very faint band with Mr = 15,000 extracellu- 
larly at the 30-min chase period, with increased intensity 
following longer chase periods (Fig. 2). Post-translational 
events could not be detected in smooth muscle cells under
U-105MG SMC
i -----  Lysate  n —  Media — i i -  Lysate-n-Media-i
Chase(min) 0 15 3 0 60 150 15 30 60 150 0 15 401801540180
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2 9 -
18 4 -
Fig. 2. Im m unoprecipitation of U -105M G  human glioma 
and vascular smooth muscle cell lysates and extracellular  
media follow ing pulse-labeling. Both cell types were pulse labeled 
with [35S]methionine, rinsed, and incubated with chase medium con­
taining unlabeled methionine as indicated. Cell lysate and chase 
media were separately immunoprecipitated with SMC-CF antiserum. 
Smooth muscle cells were preincubated with monensin which was 
present throughout the experiment. Molecular weight standards are 
indicated.
U-105MG SMC
T u n ic a m y c in  -  + +  -  +
m  w t  (kD a)
F ig . 3. The effect o f tunicam ycin on M CP-l/SM C-CF pro­
teins synthesized by U -105M G  and vascular smooth muscle 
cells (SM C). Cells were preincubated without (—) or with (+) tuni­
camycin (0.5 or 2.0 Mg/ml for U-105MG and 0.5 gg/ml for SMC) and 
metabolically labeled with [35S] methionine. Specific proteins were 
detected by immunoprecipitation of the labeling medium with SMC- 
CF antiserum as described under “Materials and Methods.”
standard conditions suggesting a very rapid modification of 
MCP-l/SMC-CF. In order to detect precursor proteins, the 
smooth muscle cells were treated with monensin to delay 
transport through the Golgi (28). Under these conditions, a 
MT = 9,000 protein appeared at the earliest time point. After 
a chase period of 15 min, a Mr = 12,000 protein appeared. 
Following a 40-min chase, the proteins detected had Mr = 
14,000 and MT = 9,000 and disappeared after a 180-min chase 
period (Fig. 2). Specific proteins were not detected extracel- 
lularly at 15- and 40-min chase periods. Following a chase 
period of 180 min, a single protein of M, = 14,500 was 
specifically detected in the extracellular medium (Fig. 2).
Glycosylation Studies—Secretory proteins are often glyco­
sylated. The cDNA sequence for MCP-l/SMC-CF predicts 
one jV-linked glycosylation site and several potential O-gly- 
cosylation sites (25). Experiments were undertaken to deter­
mine if the processing events observed above could be ac­
counted for by the addition of carbohydrate residues. Tuni­
camycin blocks transfer of carbohydrates from a dolichol 
intermediate to asparagine residues in proteins. Preincuba­
tion of U-105MG and smooth muscle cells with tunicamycin 
did not alter the migration of SMC-CF-like proteins on the 
SDS-PAGE compared with untreated cells (Fig. 3). This 
result suggests strongly that MCP-l/SMC-CF lacks aspara­
gine-linked carbohydrates.
Deglycosylation with neuraminidase removes sialic acid 
residues from carbohydrates. When treated with neuramidase,
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F ig . 4. D eglycosylation of SMC-CF proteins produced by 
U-105M G and vascular smooth muscle cells. SMC-CF-like pro­
teins from U-105MG and vascular smooth muscle cells (SMC) were 
immunoprecipitated with SMC-CF antiserum, eluted and then incu­
bated with (+) or without (—) neuraminidase (N),  O-glycanase (0), 
or glycopeptidase F (F) as described under “Materials and Methods.” 
Molecular weight standards are indicated on the left of the gels.
MCP-l/SMC-CF-like proteins from U-105MG cells exhibited 
a change in the apparent molecular mass of the high molecular 
weight MCP-l/SMC-CF-like proteins. The M, = 13,000 band 
observed in the control lane was not observed following neur­
aminidase treatment and was replaced with a single band, Mr 
= 10,500. Treatment with both neuraminidase and O-glycan­
ase resulted in a single band of Mr = 9,000 (Fig. 4). Similarly, 
for smooth muscle cells, the Mr = 14,500 band shifted to MT 
= 10,000 when cells were treated with neuraminidase and 
further shifted to Mr = 9,000 when cells were treated with 
neuraminidase and O-glycanase (Fig. 4). Incubation with 
neuraminidase and O-glycanase did not affect the migration 
of the MT = 9,000 MCP-l/SMC-CF-like proteins produced by 
either cell type. Glycopeptidase F, which cleaves IV-linked 
carbohydrates, did not change the apparent molecular weight 
of any of the MCP-l/SMC-CF-like proteins (Fig. 4). Specific­
ity was determined by the absence of a corresponding band 
in the normal rabbit serum control group (data not shown).
DISCUSSION
MG-63 osteosarcoma,4 and U-105MG glioma cells. In pulse- 
chase experiments, a MT = 9,000 protein was the first protein 
detected in all cell types. It was then modified to higher 
molecular weight proteins. All intracellular forms of MCP-1 
proteins in U-105MG cells were secreted. This contrasts with 
vascular smooth muscle cells, in which the precursor was not 
secreted. The simplest interpretation of the above results is 
that carbohydrate residues are added to a protein core of Mr 
= 9,000. The addition of carbohydrate residues causes a shift 
in mobility of MCP-l-like proteins in pulse-chase experi­
ments so that they migrate at a higher molecular weight on 
SDS-PAGE. That vascular smooth muscle cells did not se­
crete low molecular weight MCP-1 suggests that glycosylation 
events in these cells is both rapid and highly efficient com­
pared with the human malignant cells tested. The predicted 
amino acid sequence for MCP-1 contains a potential site for 
;V-glycosylation (25). However, experiments utilizing tunica- 
mycin and glycopeptidase F indicate that these potential 
glycosylation sites are not utilized. Deglycosylation experi­
ments with neuraminidase and O-glycanase indicate that O- 
linked carbohydrates are added and modified by the addition 
of terminal sialic acid residues. These results explain why the 
monocyte chemotactic factor purified from U-105MG cell line 
by Yoshimura and colleagues (25) migrated as MT = 15,000 
and Mr = 13,000 on SDS-PAGE, but the molecular weight of 
the mature protein predicted from amino acid sequence is 
only M, = 8,700. Furthermore, the predicted size of the protein 
core agrees well with our experimental data. That all MCP- 
l-like proteins migrated with M, = 9,000 after incubation 
with neuraminidase and O-glycanase suggests that the protein 
cores produced by different cell types are similar. This finding 
and the fact that the earliest protein detected in pulse-chase 
experiments had Mr = 9,000 suggests that differences in 
molecular weight are not due to post-translational proteolysis. 
In addition, the heterogeneity of MCP-l-like proteins is not 
due to the presence of different genes since Southern blot 
analysis predicts MCP-1 is a single copy gene (25). Thus, our 
results suggest that the heterogeneity of MCP-1 proteins 
produced by different cell types are due to variations in O- 
linked carbohydrate processing.
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We reported recently that all of the monocyte chemotactic 
activity produced by MG-63 human osteosarcoma cells should 
be blocked by SMC-CF antiserum, indicating that it is anti- 
genically related to SMC-CF (22). A similar monocyte che­
motactic protein termed MCP-1 is produced by U-105MG 
glioma cells in culture (24). Biochemical evidence indicates 
that MCP-1 and SMC-CF are the same proteins. This is 
consistent with our findings that antisera to SMC-CF specif­
ically immunoprecipitate MCP-l/SMC-CF proteins in U- 
105MG cells. In addition, baboon vascular smooth muscle 
cells and MG-63 human osteosarcoma cells, both of which 
produce SMC-CF, express the MCP-1 gene, whereas the 
leiomyosarcoma cell line, SKLMS, which does not produce 
detectable levels of SMC-CF, has barely detectable levels of 
MCP-1 transcripts.
The cDNA sequence for MCP-1 indicates that it possesses 
a leader sequence typical of secretory proteins. That MCP-1 
is glycosylated, secreted rapidly, and its secretion is inhibited 
by monensin (data not shown) indicates that it is a typical 
secretory protein that undergoes post-translational modifi­
cation in the endoplasmic-reticulum Golgi complex.
Studies presented here describe the processing pathway of 
MCP-l-like proteins in the vascular smooth muscle cells,
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Supplemental Material to:
Post-translational Modification of a Monocyte-specific Chemoattractant Synthesized by Glioma, 
Osteosarcoma and Vascular Smooth Muscle Cells
by
Y anting Jiang , Anthony J. Valente , Mark J. Williamson, Lei Zhang , and Dana T. Graves
MATERIALS AND METHODS
Materials - L-[”S]Methionine (710.8 Ci/mmol) was purchased from Du Pont-New England Nuclear. 
Cell culture reagents were purchased from Hazleton (Lenexa, KS). Chemical reagents were 
purchased from Sigma (St.Louis, MO) unless otherwise indicated. Deglycosylation enzymes, 
neuraminidase (acylneuraminidase hydrolase), Glycopeptidase F, and endo-1-N-acetyl- 
galactosaminidase (O-Glycanase) were purchased from Boehringer Mannheim (Indianapolis, IN) 
and Genzyme (Cambridge, MA). Monensin and Tunicamycin were purchased from Calbiochem 
(San Diego, CA).
Cells - MG-63 human osteosarcoma and SKLMS human leiomyosarcoma cell lines were purchased 
from American Type Culture Collection. Smooth muscle cells were isolated and cultured from the 
inner layer of the tunica media of baboon aortas as described by Sprague et al (26). U-105MG 
human glioma cells were a generous gift from Dr. Y. Gillespie, University of Alabama, Birmingham. 
Cells were routinely cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 
newborn bovine serum (NBS) and examined at confluence in 60 mm dishes.
Northern Blot Analysis - Total cellular RNA was isolated from primary cultures of baboon vascular 
smooth muscle cells, MG-63 and SKLMS cells by acid guanidinium thiocyanate-Phenol-chloroform 
extraction (27). Total RNA (approximately 15 ug/lane) was separated by electrophoresis on 1.5% 
agarose gels containing 6% formaldehyde and blotted onto a Genescreen Plus nylon membrane 
(Du Pont). The blot was prehybridized for 3 hours and hybridized overnight at 42nC according to 
the manufacturer. The 780 bp human MCP-1 cDNA probe (25) was obtained by Hind III and Sac 
I restriction endonuclease (New England Biolab) digestion of a pBluscript SK piasmid. The cDNA 
probe was labeled with "P-dCTP using the random primer labelling method (Promega) and applied 
at a final concentration of 1.5x10* CPM/ml. The blot was washed twice in 2x SSPE for 15 minutes, 
twice in 2x SSPE with 2% SDS at 65 C and twice in 0.1 x SSPE for 15 minutes. Blots were exposed 
to Kodak X-omat AR film with intensifying screen for 2 days at -85 C and developed. 
Immunoprecipitation Experiments - Cells were metabolically labelled by incubation in methionine- 
free minimum essential medium (MEM) for 5 hrs with [ SJmethionine (350 uCi/ml). Labelling 
medium containing secreted proteins was collected and supplemented with Triton X-100 (1%), 
EDTA (1 mM), and protease inhibitors (0.8 mM phenylmethylsulfonylfluoride (PMSF), leupeptin (10 
ug/ml), pepstatin-A (10 ug/ml)). Each sample was centrifuged to remove any cellular debris, 
aliquoted and incubated overnight at 4 C with 0.2 ul of normal rabbit serum, 0.2 ul of SMC-CF 
antiserum, or 0.2 ul of SMC-CF antiserum plus 1 ug of unlabelled purified SMC-CF. Immune 
complexes were recovered by incubation with protein-A Sepharose beads (30 ul), washed five 
times with immunoprecipitation buffer (20 mM Tris, 300 mM NaCI, 1 mM EDTA, 1% Triton X-100, 
1% crystalline bovine serum albumin (BSA), and 10 mM Nal) plus protease inhibitors, washed with 
immunoprecipitation buffer diluted 1:10 in dHOH, rinsed with dHOH and eluted with SDS-PAGE 
sample buffer (2% NaDodSO,, 0.06 M Tris, pH 6.8, 10% glycerol). Eluted proteins were separated 
by SDS-PAGE on 18% polyacrylamide gels under reducing conditions (5% 2-mercaptoethanoi) and 
examined by fluorography. In most experiments, fluorographs were exposed for four to seven 
days. The molecular mass of specifically immunnoprecipitated proteins was estimated by 
comparison with known standards.
Pulse-Chase Experiments - Cells were pre-incubated in methionine-free MEM for 15 min and then 
labeled for 15 min in methionine-free MEM plus [ 5S]methionine (500 uCi/ml). They were rinsed, 
and incubated for an additional 0-180 min in chase medium containing excess unlabelled 
methionine. At various times, chase medium was harvested and cells were placed on ice. The 
cells were rinsed with cold PBS and lysed by the addition of immunoprecipitation buffer. SMC- 
CF-like proteins were detected in the cell lysates by specific immunoprecipitation with SMC-CF 
antiserum as compared to normal rabbit control serum. To examine extracellular proteins, protease 
inhibitors (see above) and Triton X-100 (1%) were added to each chase medium sample, which was 
centrifuged and aliquoted. SMC-CF-like proteins were detected by immunoprecipitation with SMC- 
CF antiserum but not by normal rabbit serum.
Monensin and Tunicamycin Experiments - Cells were preincubated with monensin (1 or 5 uM) or 
tunicamycin (0.5 or 2.0 ug/ml) for 3 hrs. Control cells were incubated under identical conditions 
without monensin or tunicamycin. Cells were then changed to [”S] methionine labelling medium 
without or with monensin or tunicamycin and incubated for 2 hr. Labelling medium containing 
secreted proteins was immunoprecipitated with SMC-CF antiserum or normal rabbit serum and 
examined by SDS-PAGE and fluorography as described above.
Deglycosylation Experiments - For deglycosylation studies, secreted SMC-CF like proteins were 
obtained by immunoprecipitation and then incubated with the appropriate glycosidase. Briefly, 
cells were metabolically labelled for 48 hours with ["S]methionine. Labelling medium conditioned 
by cells was Immunoprecipitated with SMC-CF antiserum or normal rabbit serum as described 
above. Precipitated proteins were eluted from protein-A Sepharose beads with 100 mM acetic acid. 
Acetic acid was removed by vacuum centrifugation and samples were reconstituted with 
deglycosylation buffer (8 mM calcium acetate, 2 mM tris maleate pH 6.8, 1 mM PMSF). The 
samples were then incubated with deglycosylation enzymes: neuraminidase (25 mU); 
neuraminidase (25 mU) plus O-Glycanase (2 mU); or Glycopeptidase F (200 mU) at 37 C for 20 
hours and analyzed under reducing conditions by SDS-PAGE and fluorography as described 
above.
RESULTS OF MG-63 CELL EXPERIMENTS
Processing Studies: In MG-63 cells, a Mr = 9,000 protein alone was detected intracellularly at the 
earliest time point (Fig.5A). The Mr = 14,000 protein was specifically detected after a 15 min chase 
period in addition to Mr = 9,000 protein. Following a 180 min chase period both proteins 
disappeared intracellularly. Both Mr = 14,000 and Mr = 9,000 proteins were detected extracellularly 
at the 180 min time point (Fig.5A). The appearance of these proteins in the extracellular medium 
was substantially diminished in cells pre-incubated with monensin (Fig.5B).
Glycosvlation Studies: Preincubation of MG-63 cells with tunicamycin did not alter the migration 
of SMC-CF-like proteins on SDS-PAGE (Fig.5B). When MCP-1/SMC-CF-like proteins from MG-63 
cells were incubated with neuraminidase, the Mr =  14,000 band disappeared and was replaced by 
a band with Mr =  10,500. There was a further shift in the Mr = 10,500 band to the Mr =  9,000 band 
following incubation with both neuraminidase and O-Glycanase (Fig.5C). Incubation with 
neuraminidase and O-Glycanase did not affect the migration of the Mr = 9,000 MCP-1/SMC-CF- 
like proteins. Glycopeptidase F did not change the apparent molecular mass of any of the MCP- 
1/SMC-CF-like proteins (Fig.5C).
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Fig. 5A. Immunoprecipitation of MG-63 human osteosarcoma cell lysates and 
extracellular medium following pulse-labelling. Cells were metabolically labeled 
with [ KS]methionine, rinsed and incubated with chase medium containing 
unlabeled methionine for 0, 15, or 180 min. respectively. Cell lysate and chase 
medium were separately immunoprecipitated with SMC-CF antiserum (AS) or 
normal rabbit serum (NRS). Molecular weight standards are indicated.
Fig. 5B. The effect of monensin and tunicamycin on MCP-1/SMC-CF proteins 
synthesized by MG-63 cells. Cells were pre-incubated without (-) or with ( + ) 
monensin (1 or 5 uM) or tunicamycin (0.5 or 2.0 ug/ml) (the lower concentration 
is on the left) and metabolically labelled with [35S] methionine. Specific proteins 
were detected by immunoprecipitation of the labelling medium with SMC-CF 
antiserum as described in Methods.
Fig. 5C. Deglycosylation of SMC-CF proteins produced by MG-63 . SMC-CF-like 
proteins from MG-63 cells were immunoprecipitated with SMC-CF antiserum, eluted 
and then incubated with ( + ) or without (-) neuraminidase (N), O-Glycanase (O) or 
Glycopeptidase F (F) as described in Methods. Molecular weight standards are 
indicated.
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SUMMARY: MCP-1 is the principle monocyte chemoattractant produced by tumor cells 
in vitro. We previously identified different isoforms of MCP-1. Here we report that two 
predominant isoforms of MCP-1 (13 kD and 9 kD) can be distinguished by lectin 
binding. The results indicate that the disaccharide galactose-p1-3D-N-acetyl 
galactosamine is present on the 13 kD MCP-1 isoform but not the 9 kD isoform. 
Glycosylation of the 13 kD MCP-1 isoform does not appear to significantly change its 
antigenic properties and also does not affect its capacity to induce monocyte migration.
© 1991 Academic Press, Inc.
Monocytes play a critical role in defending the host against foreign organisms and in 
regulating the behavior of other cells. A characteristic feature of inflammation is 
infiltration of monocyte/macrophages. This infiltration is largely due to the generation 
of monocyte chemoattractants which direct the movement of monocytes from the 
peripheral vasculature. Our previous studies showed that MCP-1 is the principle 
monocyte chemoattractant produced by tumor cells in vitro (1). In addition, the 
production of MCP-1 is thought to be an important aspect of atherogenesis (2,3). We 
previously identified two predominant isoforms of MCP-1 from tumor cell medium as well 
as other minor forms (1). A significant source of MCP-1 heterogeneity is due to post- 
translational modification involving the addition of O-linked carbohydrates and sialic acid
’To whom c o r r e s p o n d e n c e  sh o u ld  be a d d r e s s e d .
A b b r e v i a t i o n : MCP-1, monocyte c h e m o t a c t i c  p r o t e i n - 1.
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residues (4). The carbohydrate moiety of glycoproteins appears to influence the 
properties of the molecules in a variety of ways. In particular, it may modify the 
physicochemical properties of proteins by changing their hydrophobicity, electrical 
charge, mass, and tertiary structure. The carbohydrate modification may serve 
important functions in cell recognition, antigenicity, increased resistance to proteolysis, 
clearance in vivo or, in some cases, may affect functional activity. In order to further 
investigate the carbohydrate structure of MCP-1 we examined the capacity of the two 
predominant MCP-1 isoforms to bind to peanut agglutinin (PNA) and wheat germ 
agglutinin. In addition, monocyte chemotaxis assays were carried out to determine 
whether glycosylation affects MCP-1 activity.
MATERIALS AND METHODS
SDS-PAGE AND TRANSFER: Two isoforms of MCP-1 were purified from U-105 human 
glioma cells following modification of the protocol described in (5). MCP-1 was 
subjected to electrophoresis on 18% polyacrylamide SDS-PAGE gels under reducing 
conditions (5% 2-mercaptoethanol) and transferred to nitrocellulose membranes.
IMMUNOBLOT: Nitrocellulose membranes were blocked (1% milk in Tris 12.2g/L NaCI 
14.6 g/L), rinsed and incubated with MCP-1 antiserum or normal rabbit serum. MCP-1 
rabbit antiserum has been previously described in (1). The membranes were rinsed 
and incubated with biotinylated goat anti-rabbit IgG antibody. Phosphatase-streptavidin 
color developer system (Bio-Rad) was used to localize the immune complexes.
LECTIN BLOT: Nitrocellulose membranes were blocked with 3% BSA. After rinsing, 
membranes were incubated with 5 ug/ml biotinylated PNA or WGA (PIERCE). For the 
negative control, biotinylated lectins were preincubated with the appropriate hapten; N- 
acetyl-D-glucosamine or D-galactosamine for WGA or PNA, respectively. For PNA, blots 
were incubated with neuraminidase overnight (0.01 Unit/ml in 50 mM sodium acetate, 
10 mM calcium acetate, 3% BSA pH 5.5) prior to addition of biotinylated PNA. The 
lectin binding proteins were identified with the phosphatase-streptavidin color developer 
system.
MONOCYTE CHEMOTAXIS ASSAY: Chemotaxis of human peripheral blood
monocytes was assessed in Boyden chambers as described in (2).
RESULTS AND DISCUSSION 
Immunoblot experiments demonstrated that both 13 and 9 kD MCP-1 isoforms were 
detected by MCP-1 antiserum but not by normal rabbit serum (Fig. 1A). Lectin blot 
experiments were undertaken to determine if MCP-1 isoforms could be distinguished
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Fig-1- MCP-1 isoforms were isolated as described in Materials and Methods. The MCP- 
1 13 kD isoform (odd numbered lanes) and MCP-1 9 kD isoform (even numbered lanes) 
were subjected to electrophoresis by SDS-PAGE (18% polyacrylamide gels) and 
transferred to nitrocellulose. A. Immunoblot: MCP-1 antiserum (1,2) or normal rabbit 
serum (3,4). B. Lectin blot: wheat germ agglutinin (1,2) or wheat germ agglutinin plus 
hapten (3,4). C. Lectin blot: peanut agglutinin (1,2) or peanut agglutinin plus hapten 
(3,4). Each result is representative of at least two experiments.
based on the capacity to bind WGA or PNA. WGA binds with high affinity to sialic acid 
and N-acetyl glucosamine (6,7). The 9 kD MCP-1 isoform was not specifically detected 
by WGA while the 13 kD MCP-1 was detected by WGA (Fig.IB). WGA preincubated 
with its hapten showed only slight non-specific binding to the 9 or 13 kD MCP-1. PNA 
binds with high affinity to D-galactose e-D-N-acetyl galactosamine (8). The 13 kD MCP- 
1 isoform was detected by PNA, while the 9 kD MCP-1 isoform did not bind PNA. The 
negative control, PNA pre-incubated with hapten demonstrated that PNA binding to the 
MCP-1 13 kD isoform was specific (Fig 1C). This result indicates that 13 kD MCP-1 
isoform contains D-galactose e1-3D-N-acetyl galactosamine disaccharides.
We tested the capacity of the two MCP-1 isoforms to induce chemotaxis of human 
peripheral blood monocytes. Monocyte chemotaxis assays demonstrated that 9 and 
13 kD MCP-1 isoforms both induced a dose-dependent increase in monocyte migration 
(Fig.2). Both had optimum activities at 1 nM. Thus, it appears that the addition of D- 
galactose-o-3D-N-acetyl galactosamine does not affect the capacity of MCP-1 to induce 
monocyte chemotaxis.
The above results indicate that the two predominant isoforms of MCP-1 can be 
distinguished by lectin binding. Results with PNA indicate that the disaccharide 
galactose-el-3D-N-acetyl galactosamine is present on the 13 kD MCP-1 isoform but not 
the 9 kD isoform. That we did not detect specific WGA binding to the 9 kD isoform 
suggests that it lacks sialic acid or N-acetyl-glucosamine residues, while either or both 
are present on the 13 kD isoform. The glycosylation of the 13 kD isoform does not
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Fig.2- Chemotactic response of human peripheral human monocytes to two different 
isoforms of MCP-1. Chemotaxis was performed in Boyden chambers following standard 
procedures under serum free conditions. Monocytes were quantified by counting the 
number of cells that had migrated per ten high power fields. Each data point 
represents the mean of triplicate samples and the assays were repeated three times. 
Insert - Silver stained SDS-PAGE of 9 kD and 13 kD MCP-1 isoforms. Each MCP-1 
isoform was purified as described in Materials and Methods. The amino acid 
composition of each isoform was virtually identical. Molecular weight standards are 
indicated on the left.
appear to significantly change its antigenic properties since both isoforms were similarly 
recognized in immunoblot experiments. Yoshimura and co-workers identified two 
isoforms of MCP-1, MCP-1 a  and MCP-1 p ,  which they reported had molecular masses 
of 15 and 13 kD respectively (5). These isoforms are likely to be the same isoforms 
that we described here with apparent masses of 13 and 9 kD, respectively. The
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difference in apparent molecular masses is likely to be due to minor variations in SDS- 
PAGE or the standards used to estimate molecular mass. Based on results reported 
here, glycosylation also does not affect the capacity to induce monocyte migration. 
Further studies are needed to establish whether glycosylation affects other biological 
functions such as resistance to proteolysis, MCP-1 clearance or other functional 
parameters in vivo.
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Section D
Unpublished Methods and Results
METHODS 
MCP-1 Purification
Human glioma U-105MG cells were cultured in roller bottles in serum free 
MEM medium. The conditioned medium was collected every 2-3 days and stored 
at -20°C until used. The conditioned medium was diluted with dH20  1:1, applied 
on the orange A dye ligand chromotographic column. The proteins bound to the 
column were eluted with 0.8 M NaCI in PBS/HsO 1:1. After dialyses against 10 mM 
acetic acid and lyophilization, the eluted proteins were applied to an HPLC cation 
exchange column (Polycat). The proteins were eluted with a NaCI gradient (buffer 
A = 5 mM NaH2P04, 1% isopropanol, pH 6.5; buffer B = 0.7 M NaCI + buffer A). 
The buffer B gradient was biphasic increasing from zero to 30% in 5 min, then to 
70% in another 40 min. Two isoforms of MCP-1, 13 kD and 9 kD were eluted with
0.35 M and 0.40 M NaCI respectively. Separated proteins were purified on reverse
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phase (CJ column with acetonitrile (buffers: A = 0.1% TFA, B = A + 80% acetonitrile) 
gradient which increased buffer B from 5% to 20% in 10 min, 20% to 23% in 5 
min, then 23% to 35% in 65 min. MCP-1 eluted from the reverse phase column at 
approximate 24% acetonitrile.
The purity of the MCP-1 fractions was examined by silver staining of SDS- 
PAGE and amino acid analysis (Harvard Microchemistry Facility, Cambridge, MA).
Murine Macrophage Chemotaxis
To increase the number of peritoneal macrophages, 1.5 ml of warmed 
peptone or thioglycolate were injected into the peritoneal cavity of the mouse. The 
cells were harvested 3-4 days after injection. Zymosan activated rat serum was 
used as a positive control in a murine cell chemotaxis assay. Chemotaxis assays 
were performed in Boyden chamber under standard conditions as described in 
section A.
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RESULTS
MCP-1 purification
Partially purified MCP-1 from orange A dye ligand column was separated 
into two peaks by cation exchange chromatography column. The proteins from 
two different peaks were then separated by reverse phase HPLC and exhibited the 
same elution profile (Fig.1). SDS-PAGE with silver staining showed a single band 
for each isoform. The amino acid analysis of different isoforms showed that the 
amino acid components for the two isoforms are the same. They are identical to 
the MCP-1 amino acid composition published by other investigators (Valente and 
others, 1988), (Yoshimura and others, 1989).
Murine macrophage chemotaxis assays
MCP-1 (9kd) chemotactic activity was tested on mouse macrophages (Table 
1). We found that proteose-peptone elicited peritoneal exudate macrophages 
respond to MCP-1 and zymosan activated serum (ZAS). Thioglycolate elicited 
peritoneal macrophages only respond to ZAS and P388.D1 macrophage cell line 
responds to neither MCP-1 nor ZAS. Furthermore, dose response experiments 
were carried out on both peptone and thioglycolate elicited peritoneal
35
macrophages. The different doses from 0.001 nM to 10 nM MCP-1 were tested.
The results demonstrated that peptone cells respond to MCP-1 in a dose 
dependent manner, with an optimal response at 5 nM (Fig.2). It is five times 
greater than the optimal concentration for human mononuclear phagocytes . This 
suggests that the response to human MCP-1 be conserved across mammalian 
species.
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Figure 1. MCP-1 purification by HPLC. MCP-1 were purified from U- 
105 human glioma cell conditioned medium as described in Methods. 
A. Two major peaks represent 13 kD (early peak) and 9 kD (later 
peak) MCP-1 from cation exchange column. B and C represent the 
profiles of the 13 kD and the 9 kD MCP-1 from reverse phase column
respectively.
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TABLE 1. Mouse Monocyte Chemotactic Assay
Cell Types
MCP- 1 (pmol/ml) Positive
Control
Negative
Control
1 0 1 0 . 1 1 : 2 5
P38 0 0 . 1 0.3 0.2 0.4
Thio 2 . 1 2.9 3.6 14.9 2 . 1
Pep 18.8 17.3 ND 22.1 4.7
Chemotactic response of mouse macrophages to human monocyte 
chemotactic protein-1 (MCP-1; 9 kD isoform). Mouse peritoneal macrophages 
were elicited by injection with proteose peptone (Pep) or thioglycolate (Thio) 
following standard procedures. The P388.D1 mouse macrophage cell line was 
also tested. Chemotaxis was performed in Boyden chambers following standard 
procedures under serum free conditions. Positive control: Zymosan activated rat 
serum diluted 1:25 in chemotaxis buffer. Negative control: Chemotaxis buffer 
alone (RPMI 1640 medium + 0.2% BSA); ND: Not determined. The results are 
presented as the mean number of the cells that migrated per high power field.
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MURINE CELL CHEMOTAXIS
DOSE RESPONSE
Num ber of ce lls  per high power field
C o n c e n t r a t i o n  o f  M CP -1  (nM)
* peptone ce lls  1 th iog lyco la te  ce lls
Figure 2. Dose response experiment of murine macrophage chemotaxis 
to MCP-1. Chemotaxis assays were performed in Boyden chamber as 
described in section A. Each data point represents the mean of 
triplicate samples.
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DISCUSSION
The objective of the first part of this study was to determine relationships 
between monocyte chemotactic factors produced by different malignant cell types. 
Factors from cell media were isolated by immunoprecipitation and chemotactic 
activity was measured. The results showed that of 13 different human malignant 
cells tested, nine synthesized detectable levels of MCP-1. All chemotactic activity 
was completely inhibited by MCP-1 antisera. The four cell lines tested that did not 
release detectable levels of MCP-1 in immunoprecipitation experiments also did not 
produce detectable amounts of chemotactic activity. These results showed the 
correlation between monocyte chemotactic activity and the synthesis of MCP-1. 
Therefore, the predominant monocyte chemoattractants produced by tumor cells 
of melanoma, glioblastoma, fibrosarcoma, rhabdomyosarcoma and osteosarcoma 
are immunologically related to MCP-1. MCP-1 thus appear to be responsible for 
most, if not all, of the nonlatent monocyte chemotactic activity produced by several 
different malignant cells.
MCP-1 derived from different cell types have different molecular masses. 
The molecular weight ranges from 9 to 15 kD. The MCP-1 gene is a single copy 
gene. Sequence analysis predicts a mature protein core of 8.7 kD. Pulse chase
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experiments were undertaken to elucidate the processing pathway of MCP-1. The
microheterogeneity of MCP-1 produced by U-105MG human glioma, MG-63 
osteosarcoma and smooth muscle cells were studied (see Section B). These 
experiments showed that the 13 and 15 kD MCP-1 proteins are derived from a 
9 kD precursor. The increase in molecular mass involves the post-translational 
addition of O-linked carbohydrates and sialic acid residues. Lectin blot analysis 
showed that disaccharide galactose-B1-3D-N-acetyl galactosamine and sialic acid 
or N-acetyl-glucosamine is present on the 13 and 15 kD MCP-1 isoform but not 
the 9 kD isoform (see section D). Secretion of these proteins occurs rapidly 
following processing events in the endoplasmic reticulum-Golgi compartment. 
Vascular smooth muscle cells only secret glycosylated MCP-1. In contrast, the 
tumor cells or inflammatory stimulated cells produce both glycosylated and non- 
glycosylated MCP-1. It is possible that under pathological conditions, accelerated 
secretion of MCP-1 results in an incomplete protein modification since some MCP- 
1 proteins are secreted without glycosylation. Glycosylation of MCP-1 does not 
appear to significantly change its antigenic properties. It also does not affect the 
capacity to induce monocyte migration. However, glycosylation may affect other 
biological functions such as resistance to proteolysis, MCP-1 clearance or other 
functional parameters in vivo. The diversity and complexity of the carbohydrate
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moiety of glycoproteins suggest that they are functionally important. For example,
the removal of glycoproteins from the circulation is accomplished by carbohydrate­
binding proteins on liver cells. When terminal sialic acid residues of glycoproteins 
are removed by sialylases on the surface of blood vessels, the exposed galactose 
residues on the glycoproteins are recognized by asialoglycoprotein receptors in 
the plasma membranes of liver cells. Then the complex of asialoglycoprotein and 
its receptor is internalized by the liver cells so that the glycoproteins are removed 
from blood. The rate of removal of sialic acids from glycoproteins is controlled by 
the structure of the protein itself (Stryer, 1988). There is no information yet on 
how MCP-1 is removed or degraded from sites in vivo. I would speculate that the 
half life of glycosylated MCP-1 may be different from the non-glycosylated isoform. 
Since MCP-1 is locally secreted and functions at a given site, it is likely to be 
removed by local clearance mechanisms. MCP-1 may be degraded by proteases, 
or be functionally removed by interaction with specific binding proteins. 
Alternatively, it could be sequestered by non-specific binding to extracellular matrix 
proteins. Since carbohydrate residues may protect the protein core from 
proteases, the glycosylated MCP-1 may be more stable. Carbohydrate residues 
could also change the interactions of MCP-1 with binding proteins and extracellular 
matrix components. Non-glycosilated MCP-1 may have different binding affinities
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to potential binding proteins or matrix proteins. The latter possibility in particular
is supported by our studies demonstrating that non-glycosilated MCP-1 binds with 
greater avidity to cation exchange columns than the glycosylated isoform (see 
Section D).
Yoshimura and coworkers (Yoshimura and others, 1989) reported that under 
conditions of high stringency, MCP-1 cDNA hybridized with genomic DNA 
restriction fragments from chimpanzee and baboon, but not rat or mouse. 
However, we showed that peptone elicited mouse peritoneal macrophages could 
respond to MCP-1, which is consistent with the fact that the mouse JE gene has 
68% homology with MCP-1. This suggests that the response to MCP-1 is 
conserved across mammalian species, and the active site of MCP-1 is relatively 
well conserved in the JE gene. These studies showed that in vivo studies using 
human MCP-1 could be carried out on the mouse. Another finding of these 
studies is that thioglycolate stimulated mouse peritoneal macrophages respond to 
C5a (complement-5 in zymosan activated serum) but not to human MCP-1. It 
indicates the specificity of cell stimulations and responses. The reason for the lack 
of response by thioglycolate stimulated macrophages to MCP-1 is not clear. 
Thioglycolate is a chemical used for inducing exudation of cells into the peritonium 
of mice. The induced peritoneal macrophages show characteristic inflammatory
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changes are termed "activated". One possibility is that mouse peritoneal
macrophages have lost MCP-1 receptors as they are activated by thioglycolate. 
A remote possibility is that thioglycolate and MCP-1 stimulate macrophages 
through the same pathway, so that thioglycolate stimulated macrophages are de­
sensitized to MCP-1. Another puzzling finding is that P388.D10 cultured 
macrophage cell line did not respond to either C5a or MCP-1. This may be 
explained by Wilkinson's postulation that "macrophages newly derived from 
monocytes retain locomotor capacity, but prolonged residence in the unstimulated 
peritoneal cavity causes the cells to lose locomotor capacity" (Wilkinson and 
others, 1988). P388.D10 cells may be similar to unstimulated macrophages.
Other investigators and my studies demonstrated that many tumor cells 
produce MCP-1 constitutively while most normal cells produce MCP-1 only under 
stimulation by inflammatory mediators (rev. in Oppenheim and others, 1991). This 
indicates that the MCP-1 gene is "turned on" during human tumorigenesis. It also 
suggests that MCP-1 may play an important role in tumor development. MCP-1 
is postulated to attract monocytes into the tumor, which mature into tumor 
associated macrophages. Tumor associated macrophages have varied and 
diverse functions in tumor development. They could either kill the tumor or 
paradoxically facilitate tumor growth and metastasis (McBride, 1986). Most efficient
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tumor killing is done by direct contact between macrophages and tumor cells.
The tumoricidal activities of macrophages could be accomplished by production 
of soluble factors, such as H20 ? C3a, proteinases and cytokines. Based on in vitro 
studies, the ratio of the target and effector cells is critical in macrophage-mediated 
tumor killing (Stewart and others, 1989) and tumoricidal efficiency also depends 
on the susceptibility of the target cells. Besides direct macrophage mediated 
cytotoxicity, macrophages can kill tumor cells in the presence of antibodies. MCP- 
1 could help the host defense system to inhibit tumor growth in several ways.
First, MCP-1 could attract a large number of monocytes into the tumor, so that the
s
ratio of effector to target cells increases. Second, if MCP-1 can up-regulate 
monocyte adhesion molecules qualitively and/or quantitively, it may promote 
contact dependent tumor killing by increasing monocyte attachment to the tumor 
cells. Third, MCP-1 also could inhibit tumor growth by activating monocytes to 
produce cytotoxic factors and cytokines. Monocytes are a major source of IFN 
(interferon), TNF (tumor necrosis factor), and IL-1 (interleukin-1) (Nathan, 1987).
Each of these cytokines alone or by cooperating with other factors could kill tumor 
cells. If MCP-1 can induce monocytes to produce any of them, it could 
theoretically aid the host defence against tumor growth.
Despite the potential for MCP-1 stimulated monocytes to inhibit tumor
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growth, apparently tumors grow in the presence of macrophages. Probably, the
mutual selection between tumor and tumor associated macrophages results in a 
"progressing" tumor and the selection of macrophages beneficial to tumor growth. 
The progressing tumor begins with a few tumor cells, which have escaped from 
the host defence system. These tumor cells form a tumor and grow in the host. 
Macrophages are major producers of many growth factors, which may favor tumor 
cell proliferation. Macrophages can produce enzymatic factors such as 
collagenase and other proteinases to dissolve the surrounding tissue and facilitate 
the tumor invasion. Angiogenic factors produced by macrophages could enhance 
the vascular supply to the tumor (Polverini and others, 1977). This may be 
important since tumor growth is dependent upon an adequate blood supply.
MCP-1 is not only expressed by tumor cells, but also expressed by normal 
cells under the stimulation of inflammatory mediators. Therefore, elevated MCP-1 
expression may be found in many chronic inflammatory diseases, which are 
characterized by mononuclear phagocyte infiltration.
The studies on atherosclerosis proved that MCP-1 may be an important 
mediator in human diseases. MCP-1 is expressed in atherosclerotic lesions but 
not in normal blood vessels (Nelken and others, 1991). The atherosclerotic lesions 
consist of fatty streaks and fibrotic plaques, which contain excessive macrophages,
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smooth muscle cells and accumulated extracellular matrix. Low density
lipoproteins induce MCP-1 production by smooth muscle cells and endothelial cells 
which may be responsible for monocyte transmigration into the subendothelial 
space (Cushing and others, 1990) (Navab and others, 1991). The infiltrating 
monocytes differentiate into macrophages, which could contribute to the 
pathological progress of the disease by several means. Under physiological 
conditions, macrophages are responsible for removing low density lipoproteins 
from the intima, but the receptors on macrophages only recognize these 
lipoproteins in a modified form. Activated macrophages produce free radicals to 
further oxidize low density lipoproteins (OX-LDL), which is cytotoxic. When OX-LDL 
accumulates inside the macrophages, foam cells are formed. The presence of 
foam cells is characteristic of pre-atherosclerotic lesions, fatty streaks. When the 
quantity of the OX-LDL exceeds the capacity of macrophages to remove it from 
the intima, accumulated OX-LDL injures or kills intimal cells including the foam cell. 
This results in a necrotic extracellular lipid core, a key step in lesion formation. 
Macrophages may also participate in the pathological process of the disease by 
releasing stimulatory factors such as PDGF (platelet-derived growth factor), and 
IL-1 (Ross and others, 1990) (Dinarello, 1991). PDGF induces migration of the 
smooth muscle cells from media to the intimal layer, where they proliferate under
45
the stimulation of PDGF and IL-1. In addition to macrophage and smooth muscle
cell accumulation, macrophage-derived factors also stimulate collagen production 
by smooth muscle cells. The accumulated lipids, cells and extracellular matrix in 
the intima form the fatty streaks and fibrotic plaques. Thickened intima narrows 
the lumina of the blood vessels, which results in the obstruction of the blood flow.
As has been suggested for atherosclosis, MCP-1 may also be an important 
mediator in idiopathic pulmonary fibrosis (IPF). IPF is clinically characterized by 
a progressive reduction of lung function in air exchange between alveoli and 
capillaries. A pathologic characteristic of IPF is macrophage infiltration in the 
interstitium of the lung, where increased MCP-1 expression might occur. MCP-1 
could be responsible for the accumulation of the macrophages in the interstitium. 
Activated macrophages produce PDGF, which is a mitogen for proliferation of 
fibroblasts and stimulates collagen synthesis by fibroblasts. Infiltration of 
inflammatory cells, excessive proliferation of fibroblasts and accumulation of 
collagen result in a thickened interstitium, which leads to a reduction of air 
exchange between alveolus and capillaries.
MCP-1 may be expressed in many other chronic inflammatory diseases. For 
example, in rheumatoid arthritis, MCP-1 could be responsible for the infiltration of 
mononuclear phagocytes in synovial tissue or fluid. Infiltrated macrophages
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produce multiple factors such as IL-1 and IL-6 that cause acute symptoms and
lead to degradation of cartilage.
MCP-1 may also be a mediator in the inflammatory diseases caused by 
bacterial infection. For example, in periodontal disease including gingivitis and 
inflammatory periodontitis, bacteria are thought to be the initial pathogens. Like 
other inflammatory diseases, gingivitis is characterized by inflammatory cell 
infiltration. When the inflammatory lession of gingiva progresses to involve the 
periodontium and bone tissues, it is called periodontitis. A bacterial product, LPS 
(lipopolysacchride), and/or other inflammatory factors can stimulate epithelial and 
connective tissue cells to produce MCP-1 in vitro (Oppenheim and others, 1991). 
If this is also true in vivo, MCP-1 may be responsible for macrophage infiltration 
observed in inflamed gingiva. Antimicrobial activities of macrophages are 
accomplished by contact-dependent cytotoxicity and/or release of free radicals, 
cytokines, enzymes, and proteases. Macrophages also remove pathogens by 
phagocytosis. Besides direct microbicidal activities, macrophages help the host 
defence by initiating the immune responses. As antigen presenting cells, 
macrophages stimulate T-lymphocyte proliferation and indirectly stimulate B- 
lymphocyte proliferation and antibody production. These are protecting functions 
of macrophages. However, macrophages also have destructive power. Activated
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macrophages produce factors such as IL-1, PGE-2, and metalloproteinases.
These molecules are thought to be responsible for connective tissue degradation 
and bone resorption in periodontitis.
Macrophages participate in normal wound healing. Therefore, MCP-1 may 
be expressed in the area in which acute injury occurs. It is supported by the 
evidence that the expression of MCP-1 increases during the early reflow period of 
renal ischemia (Safirstein and others, 1991). The chemotactic and inflammatory 
properties of MCP-1 would suggest that it may attract monocytes into the ischemic 
kidney. Recruited monocytes could remove the dead cells and secret multiple 
regulating factors to promote the migration and proliferation of regenerating cells. 
Macrophage-derived growth factors, such as transforming growth factor-alpha and 
fibroblast growth factor, are stimulators for epithelium growth (Aaronson and 
others, 1990), so they can help to restore the integrity of the tubule epithelium.
The effects of the MCP-1 on tumorgenesis and inflammatory diseases are 
complicated by secondary effects of its target cell, mononuclear phagocytes. After 
monocytes migrate to the infected sites, other factors may affect the functions of 
mononuclear phagocytes. Moreover, MCP-1 itself may directly regulate infiltrated 
mononuclear phagocytes. Based on the studies with a functionally similar 
chemotactic factor, fMLP (Miller and others, 1987), it is very likely that MCP-1
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stimulates beta-2 integrin expression on monocytes. If this is true, MCP-1 would
play more extensive roles in contact-dependent activities of mononuclear 
phagocytes. These contact-dependent functions include: adhesion, phagocytosis, 
and contact-dependent tumor killing. MCP-1 may also stimulate immune 
responses by mediating antigen presentation and cytokine production by 
macrophages. Multiple receptors are involved in antigen presentation. After 
endocytosis and modification by macrophages, antigens are presented to T-helper 
cells with the la molecule, a Major Histocompatibility Complex Class II antigen 
expressed on the macrophage surface. Macrophages also express ICAMs 
(intercellular adhesion molecule-1 and 2) and LFA-3 (lymphocyte function-related 
antigen-3) which are counter receptors for LFA-1 and LFA-2 (lymphocyte function- 
related antigen-1 and 2) on lymphocytes respectively (Springer and others, 1990). 
The interactions between ICAMs and LFA-1, and between LFA-3 and LFA-2 are 
required for T-cell activation (Springer and others, 1990). If MCP-1 could activate 
or induce the expression of one or more of these molecules: ICAM-1, ICAM-2, 
LFA-3 or la on macrophage surfaces, it may directly enhance the antigen 
presentation by macrophages. The presented antigens and produced second 
signals such as IL-1 by macrophages activate T-lymphocytes, latter then release 
lymphokines such as IL-2 and IL-4. These lymphokines stimulate T and B
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lymphocyte proliferation, and antibody synthesis.
MCP-1 may play more profound roles in host defence by producing 
regulatory factors. Cytotoxic cytokines, enzymes or free radicals produced by 
mononuclear phagocytes can help the host to kill invading organisms or tumor 
cells. On the other hand, these molecules could also damage normal tissue. 
Similarly, growth factors produced by macrophages can stimulate cell proliferation 
and extracellular matrix deposition. In normal wound healing, macrophages 
phagocytose tissue debris and dead cells to clean the wound. Macrophages also 
promote the migration and proliferation of regenerated cells by producing 
stimulatory factors. Macrophages produce PDGF, FGF, TGF and IL-1, which is 
chemotactic and/or mitogenic for connective tissue, endothelial and epithelial cells 
(Leibovich and others, 1988). These stimulating factors are thought to be essential 
for normal wound healing. However, in other cases, the growth stimulating effects 
of these macrophage-derived factors may result in hyperplasia of the tissue. This 
"unwanted” cell proliferation and matrix deposition may interfere the function of the 
involved organ. Thus, it depends on the specific factors produced in particular 
conditions whether infiltrated mononuclear phagocytes help the host to fight the 
disease or promote pathologic process of the diseases. Therefore, the expression 
of MCP-1 itself could be a positive event, but also may lead to the negative
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consequence.
Based on the studies mentioned in this thesis, the expression of MCP-1 in 
vivo may represent a common mechanism for recruitment of monocytes in 
pathologic conditions such as tumors, chronic diseases such as atherosclerosis 
and acute injuries. Besides chemotaxis, MCP-1 would be expected to directly 
regulate the function of mononuclear phagocytes because of effects of other 
chemoattractants. Like most immunoregulatory factors, MCP-1 could lead to both 
positive and negative results for the host. The further studies on MCP-1 regulated 
monocyte/macrophage function hold great promise. It will help us to understand 
the mechanisms of the pathological or physiological situations, which are 
predominated by mononuclear phagocytes.
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SUMMARY AND CONCLUSIONS
Monocytes play a critical role in defending the host against foreign 
organisms and in regulating the behavior of other cells. A characteristic feature 
of macrophages is their ability to infiltrate tumors. Human malignant cells secrete 
low molecular size proteins that attract peripheral blood monocytes and may be 
responsible for the accumulation of tumor associated macrophages observed in 
vivo. Similar chemotactic proteins produced by cultured vascular smooth muscle 
cells and U-105MG human glioma cells have also been identified and termed 
SMC-CF and MCP-1 respectively. Biochemical evidence indicates MCP-1 and 
SMC-CF are the same protein. In section A, the potential relationship between 
chemotactic factors produced by different cell types was investigated. In section 
B, their processing pathway and the microheterogeneity of MCP-1 were elucidated. 
In section C, the possible carbohydrate structure of MCP-1 was studied. In 
section D, the capability of mouse macrophages chemotactically responding to 
human MCP-1 was tested. Based on my studies, I conclude as following:
1. Monocyte chemotactic factors produced by malignant cells belong 
to the family of monocyte chemoattractant protein-1 (MCP-1).
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2. MCP-1 is responsible for most, if not all of the latent chemotactic 
activity produced by those malignant cells.
3. All isoforms of MCP-1 are derived from a Mr = 9000 precursor and 
the post-translational modification involves the addition of O-linked 
carbohydrates and sialic acid residues.
4. Post-translational modification of MCP-1 processes through the 
endoplasmic-reticulum Golgi complex.
5. Sialic acids and disaccharide galactose-beta-1-3D-N- 
acetylgalactosamine are present on the 13 kD MCP-1 isoform but not 
the 9kD isoform.
6 . Glycosylation of the 13 kD isoform does not appear to significantly 
change its antigenic properties and does not affect its capacity to 
induce monocyte migration.
7. The response to MCP-1 is conserved across mammalian species.
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